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Abstract 
Liver biopsy is a gold standard for detecting liver fibrosis. However, it is 
invasive and subject to sampling error. Non-invasive predictors are therefore urgently 
needed. Surface-enhanced laser desorption/ionization (SELDI) Proteinchip technology 
is a useful tool for biomarker discovery. Nevertheless, the main drawback is its 
incapability of obtaining protein identity of a biomarker. The aims of the study were to 
establish an automated magnetic bead-based proteomic profiling technology, and to 
identify proteomic markers for detecting liver fibrosis in patients with chronic.hepatitis 
B virus (HBV) infection using the established technology. 
We successfully established an automated magnetic bead-based technology for 
high-throughput quantitative serum profiling, which can greatly reduce batch to batch 
variation and increase reproducibility. The intra-assay and inter-assay coefficients of 
variation (CV) of the quantitative proteomic profiling assay were evaluated to be less 
than 30%. It allowed simultaneous analytic profiling and obtaining preparative 
proteome fractions for subsequent protein identification experiments. 
In the 2nd of the study, the established automated proteomic profiling 
technology was applied to analyze 214 treatment-naive and post treatment chronic HBV 
infected patients with different degrees of liver fibrosis (Ishak score 0-6). Quantitative 
proteomic profiling was obtained by using CI8 hydrophobic magnetic beads and strong anion 
exchange (SAX) beads and analyzed by Matrix-Assisted Laser Desorption/ionization 
Time-of-Flight Mass Spectrometry (MALDI-TOF MS). Linear regression method (forward 
stepwise) was used to develop a diagnostic model for predicting the degrees of liver fibrosis 
from the serum proteomic profiles, clinical data, serological data, and biochemical data. 
Pre-treatment samples were used to develop diagnostic model. 4 proteomic features, platelet 
count, HBV DNA, bilirubin and prothrombin time were found to be associated with the degrees 
of liver fibrosis. By linear regression method (forward stepwise), two proteomic features {m/z 
i 
9，165 and m/z 12,443) and prothrombin time was included in the diagnostic model. Post-
treatment samples were used for independent validation. In the independent validation, the 
AUROC curve was 0.750 (76% sensitivity, 79% specificity), m/z 9,165 proteomic feature was 
identified as apolipoprotein C-III. 
In conclusion, serum proteomic fingerprint is a good non-invasive method to 



















硏究結果發現 ’ 4個標誌蛋白、血小板計數、HBV脫氧核糖核酸、膽紅素 
和凝血酶原時間的變化均與肝臟纖維化有關。經過線性迴歸(linear regression)順 
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Review of literature 
1 
Overview of liver fibrosis 
Liver fibrosis is a scarring process caused by chronic liver injury. This wound-
healing response leads to the accumulation of fibrillar extracellular matrix (ECM) 
components which causes the progressive distortion of the hepatic architecture and 
eventually loss of hepatic function. [1] Liver fibrosis can be induced by different 
etiologies such as hepatitis B or C viral infection, alcoholic and nonalcoholic 
steatohepatitis (NASH). [2] It is a step-by-step process starting from minimal fibrosis 
which is usually undetectable, followed by liver cirrhosis and ultimately ending in liver 
cancer. Hepatitis B and C, two major causes of chronic liver diseases (CLD), are 
endemic in worldwide with 350 million and 170 million people live with chronic 
infection respectively. [3] Hepatitis C remains the most common cause of CLD in 
western countries such as the United States and European countries while it is not 
common in Asia. On the contrary, hepatitis B is common in Asia especially in China. 
The prevalence of chronic hepatitis B is also high in Asia relative to Europe. 75% of the 
chronically infected population is in Asia while less than 1% of the chronic population is 
found in Western Europe and North America. Fung et ai reported that the prevalence of 
severe fibrosis in chronic hepatitis B was 34% in an Asian cohort, they also showed that 
hepatitis B was a leading cause of liver fibrosis, cirrhosis and liver cancer. [4] Other 
factors such as antioxidants, hepatic iron stores, age, HIV coinfection and obesity are 
considered to enhance hepatic injury [5][6] and thus increase the progression of liver 
fibrosis. 
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Pathophysiology of liver fibrosis 
Fibrosis is a dynamic process and evidences show that it is reversible even in 
advanced fibrosis. [7] It is governed by the turnover rate of ECM which include 
glycoproteins, collagens and proteoglycans. ECM can be synthesized by hepatocytes, 
bile duct epithelial cells and endothelial cells but is mainly made by fibroblastic cell 
population. [8] Once these cells are injured, the composition of hepatic ECM changes 
and the liver becomes fibrotic. 
Historically hepatic stellate cell (HSC) has been considered as the key 
contributor for the abnormal deposition of fibrillar ECM. [9] It is also known as lipocyte, 
ito cell or perisinusoidal cell which stores vitamin A. Upon hepatic injury, ‘‘quiescent” 
stellate cell will become "activated", changing from vitamin A-storing cell to 
myofibroblast-like cell with morphological and functional changes. [10] Morphological 
changes include loss of vitamin A and increase in rough endoplasmic reticulum while 
functional changes consist of increase in collagens, fibronectin, laminin and 
proteoglycans secretion. [11] Following HSC activation, gene expression pattern also 
changes; for example, a remarkable increase in types I and III collagens and expression 
of HSP47, a collagen-binding stress proteins reported as a collagen-specific molecular 
chaperone during collagen biosynthesis. [12] In addition, HSC activation can be 
mediated by induction of signaling cascades. Several signaling cascades, transforming 
growth factor beta (TGF-P), connective tissue growth factor (CTGF) and platelet-
derived growth factor (PDGF) can control the induction of gene expression and 
fibrogenic response of HSC during liver fibrosis. [13-15] 
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The synthesis and degradation of ECM must be maintained in a critical balance 
and is tightly regulated by matrix metalloproteinases (MMPs)-mediated turnover of 
ECM proteins. [16] MMPs can destroy ECM by cleaving native collagen through the 
helical proportion of the molecule. On the contrary, natural inhibitors, tissue inhibitors 
of metalloproteinases (TIMPs) block and control the ECM turnover by interacting with 
the active sites of MMPS in non-covalent manner. Therefore, the occurrence of fibrosis 
is due to the decreased activity of MMPs made by the overexpression of TIMPs. [17] 
In addition, Kupffer cells, specialized leukocytes present in the liver, can also cooperate 
with cytokines released by infected liver cells to stimulate stellate cell to produce 
collagen fibers. [18] 
Fibrosis in chronic viral hepatitis patients is a dynamic process that occurs 
throughout one or two decades to reach cirrhosis and even longer for liver cancer. 
Initially, it is limited to the portal tracts which cause portal hypertension to the patients, 
followed by extensive fibrosis septa occurring in the liver parenchyma and ended by 
septum formation and rings of scars surrounding nodules of hepatocytes. [19] 
Histological classification of liver fibrosis 
As liver fibrosis takes years or decades to develop, it is essential to monitor the 
status of liver fibrosis so that clinicians can make good use of this important parameter 
to assess the risk of disease and make therapy decision. It is particularly valuable for 
patients who are in compensated state since therapy at right time is critical for the 
reversal of fibrotic state in the liver. 
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Liver biopsy is the gold standard for staging liver fibrosis. It allows direct 
histological examination of liver for diagnosis and prognosis. With new insights of liver 
fibrosis under different etiologies, grading of liver fibrosis aims to confirm clinical 
diagnosis, describe and quantify necroinflammation and fibrosis, evaluate possible risk 
of disease and assess the treatment progress. [20] Several semiquantative scoring 
systems have been used recently, namely histological activity index (HAI), Ishak's score 
and METAVIR scoring system. 
HAI 
HAI scoring system was developed in 1981 by Knodell and colleagues. [21] It is 
a combined score classified into four categories: periportal necrosis (1-10); parenchymal 
damage (0-4); portal inflammation (0-4) and fibrosis (0-6). The score for each category 
is discontinuous and with weighting. Periportal necrosis has the greatest weighting 
among others because of its greatest influence in determining the activity and severe of 
chronic aggressive (active) hepatitis (CAH). [22] 
HAI was the first reproducible histological scoring system in assessing liver 
biopsy. With a total score of 22，it provides a broad range of scores which can 
differentiate small differences between biopsies. However, the main frequently cited 
criticism is the combination of necro-inflammation (grading) and fibrosis (staging) in 
the existing system should be separately assessed due to their differences in nature. [23] 
Ishak score 
Due to the inappropriate combination of necrosis and fibrosis, a modified HAI 
grading and staging was developed. It allows separate assessment in grading and staging. 
Grading is used to describe the intensity of inflammation while staging refers to the 
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amount of fibrosis detected by liver biopsy. [24] Another modification upon traditional 
HAI is that it has continuous range in nature. In modified HAI grading, there are four 
categories with the maximum possible grading score of 18. 
In staging, fibrosis, architectural disturbance and cirrhosis are important features 
needed to consider. Staging ranges from no fibrosis to definite cirrhosis (Ishak score 0-
6). An Ishak score > 2 indicates the presence of significant fibrosis and an Ishak score > 
4 indicates the presence of liver cirrhosis. [25] 
METAVIR scoring system 
METAVIR scoring system was developed specifically for patients with hepatitis 
C. It also assesses grading and staging separately. The grading score ranges from 0 (no 
activity) to 3 (severe activity) and the fibrosis score (staging) is a 5-point scale from 0 
(no fibrosis, no scarring) to 4 (cirrhosis, advanced scarring). [26] 
Gold standard for fibrosis assessment - Liver biopsy 
Liver biopsy has long considered as the gold standard to diagnose the presence 
of fibrosis and stage the disease. It is a direct method for assessing liver injury, 
providing information on fibrosis, inflammation, necrosis, steatosis and hepatic iron load. 
[19] In addition, it allows the identification of suspected and unexpected cofactors as 
well as comorbidities. However, there are several limitations that hinder the use of liver 
biopsy. Researchers started to focus on the development of non-invasive methods to 
assess liver fibrosis. Liver biopsy is an invasive method and may cause patients 
suffering from pain and complications, especially for patients with prolonged 
prothrombin time and low platelet count as excess bleeding may occur after tissue 
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collection. Cadranel et al. reported that 20% and 0.57% of the patients in the study 
group suffered from pain and severe complication respectively. [27] The other criticism 
is sampling error. As only 1/50,000 of the whole liver is examined, the biopsy result 
may not reflect the full picture of the entire liver. Reports showed that discordance of 
fibrosis stages occurs in left and right lobes of liver for the same patient. [28] [29] In 
addition, the size of the tissue greatly affects the diagnostic accuracy of liver biopsy. 
Colloredo et al reported that smaller sample might give milder stage and thus staging 
will be significantly underscored. [30] Another well-known drawback is inter-observer 
variability among pathologists which gives uncertainty on the accuracy of liver biopsy. 
[29] 
On the other hand, its invasive nature also gains reluctance from patients. 
Because of this, it is not able to monitor treatment progression which is definitely 
important for antifibrotic therapies. It is costly as patients require hospitalization for 6-
18 hours and consumes manpower issues. [19] Because of the sampling error, observer 
variation and invasive nature in examining liver biopsy, new noninvasive tests for 
detecting liver fibrosis are likely to have a role in the future. 
Biomarker in blood - noninvasive method for assessing diseases 
Human blood contains huge amount of proteins and is thought to be a reservoir 
of biomarkers. Liotta et al pointed out that every cell would leave a record of its 
physiological state by producing a product that shed to the blood. Their relative cellular 
abundance, together with cleaved or modified form, can reflect the ongoing 
physiological and pathological events. [31] More publications showed that the 
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peptidome (peptides less than 50,000 Da) might contain rich unstudied disease-specific 
diagnostic biomarkers. [32] 
By Food and Drug Administration (FDA) definition, "diagnostic" includes 
determining the disease risk, screening for diseases and confirming the suspected 
diseases. It covers determining prognosis or staging the diseases as well as monitoring 
treatment response. [33] A good biomarker should have properties including good 
sensitivity, specificity and strong association with the diseases. Furthermore, it should 
be useful in the majority of the population and have strong diagnostic, prognostic and 
predictive significance. [34] 
With an enormous diversity of proteins in blood which is readily accessible from 
patients with minimal pain, it is the best source for detecting diseases. However, its 
complexity gives researchers a great challenge in biomarker discovery. Lack of 
sensitivity and specificity are still the major obstacles for current biomarkers. Only few 
biomarker assays have been submitted to FDA for approval though an overwhelming 
interest in biomarkers discovery rose in the past decades. [33] To get approved from 
FDA, the new assay should be able to establish adequate analytical (accuracy and 
precision) and clinical (sensitivity, specificity and some indication of clinical utility) 
performance. Several successful examples include prostate-specific antigen (PSA) for 
prostate cancer and alpha-fetoprotein (AFP) for liver cancer. Failure in fulfilling the 
requirements can be explained by heterogeneity among patients. The severity of diseases 
and epidemiological heterogeneity including age, sex, ethic and genetic background can 
reduce the specificity of biomarkers. 
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Despite of these challenges, there is a growing interest in biomarker discovery 
field. With more advanced technologies and increasing knowledge of the 
pathophysiology of diseases, more good quality biomarkers can be discovered and 
accepted by FDA for clinical use. 
Significance of non-invasive markers of liver fibrosis 
Due to the invasive nature and limitations of liver biopsy, serum markers offer 
an attractive alternative to liver biopsy. There has been considerable interest in non-
invasive tests for accurate assessment of liver fibrosis. The main merits of serum 
markers are non-invasive and readily accessible from patients. It is cost effective and 
less manpower is needed compared with liver biopsy. Liver biopsy needs to be obtained 
by hepatologists or radiologists [35] while nurses or skilled medical workers can help 
patients taking blood for assessment and no hospitalization is required. Minimal pain in 
blood taking makes it more versatile and easily accepted by patients. Also, severe 
complication is unlikely to occur during blood taking. This enables the evaluation of the 
efficacy of treatment regimens as patients are pleased to back to clinics for continuous 
assessment. 
Yet, no true serum marker has been validated to date and acted as a surrogate 
marker of liver fibrosis. [1] Limitations of current non-invasive serum markers include 
inadequate reproducibility, sensitivity and specificity of the marker, giving at least 20% 
expected rate of misdiagnosis for non-invasive models. [19] Moreover, most non-
invasive markers reported in literatures can classify well for severe cases like cirrhosis 
[36] but are lack of reliable identification and classification of the early stage cases. 
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In order for non-invasive markers to be implemented in clinical practices, some 
requirements should be fulfilled. Sebastiani et al proposed that an ideal non-invasive 
marker for liver fibrosis should be liver specific, easy to perform and able to provide 
information on fibrosis stage and fibrogenesis activity. It is even better if the half-life 
and excretion route is known and independent of comorbidities. More importantly, the 
biomarker should be sensitive enough to discriminate between different fibrosis stages 
and reproducible across different centers. [19] 
Biomarkers of liver fibrosis 
Serum markers of liver fibrosis can be classified into two categories, direct and 
indirect markers. [1][34] Direct markers are those reflect the ECM turnover which are 
thought to be closely related with deposition of ECM in liver. They may be the 
structural elements of fibrogenesis or key mediators involved in degradation of fibrosis. 
Indirect markers reflect perturbations in liver function. They have potential to directly 
reflect morphological, functional, and metabolic changes of the liver, monitoring the 
progression of liver diseases. 
Direct markers 
With clearer insight into the mechanism of liver fibrosis, researchers start to 
investigate the components involved in the ECM biosynthesis and degradation, 
searching for potential markers particularly govern the ECM turnover and correlate with 
the stages of liver fibrosis. Potential markers include compounds from collagen 
synthesis or degradation, enzymes in matrix biosynthesis or degradation, ECM 
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glycoproteins and proteoglycans. The mechanism of liver fibrosis is independent of the 
etiologies of the liver injury, as no obvious difference is found in the progression of 
fibrosis. Therefore, it is believed that direct markers can be implemented to all liver 
fibrosis patients with different etiologies. However, the costs of checking those direct 
markers are so high that it is not routinely available in most clinical setting. There are 
some currently available direct biomarkers, namely hyaluronic acid (HA),丨aminin， 
YKL-40 (Chondrex), type I and IV collagens and cytokines. [37] HA is a 
glycosaminoglycan found in virtually all connective tissues and in liver fibrosis. It is a 
component of ECM synthesized by HSC. HA is increased particularly in cirrhosis 
patients and gives better sensitivity and specificity to cirrhosis than fibrosis. [38] It can 
be concluded that HA may be a good marker in excluding cirrhosis but not for fibrosis. 
It is included in some non-invasive models such as Hepascore and FibroSpect score. [39] 
[40] Laminin is a major noncollagenous glycoprotein synthesized by HSC. [41] It 
increases during fibrosis due to alcohol consumption and viral hepatitis and shows 
reasonable performance with greater than 80% accuracy. [42] It is deposited around the 
vessels, in the perisinusoidal spaces and portal tracts. [34] YKL-40 is a glycoprotein in 
chitinase family. It is a relatively new marker of liver fibrosis. The cellular source is 
supposed to be activated HSC. [43] Although its physiological function is unknown, it is 
believed that YKL-40 may be a growth factor for fibroblasts, chondrocytes, and 
synovial cells. It is also a migration factor for endothelial cells. 
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Indirect markers 
Indirect markers can be further classified to routine serum tests markers and 
imaging test. Based on readily available biochemical parameters from routine blood 
tests, researchers found a number of them that were correlated with the severity of liver 
fibrosis and could be served as an indication of liver function. The use of those indirect 
markers is cheaper compared with direct markers and liver biopsy. Several non-invasive 
models were constructed for detection of liver fibrosis and their corresponding 
diagnostic accuracies were summarized in Table I. Nevertheless, these models were 
greatly limited by lacking external validation and therefore further extensive 
investigation was needed. Naveau et al. reported that FibroTest was the best models of 
liver fibrosis among all non-invasive models [49] while other studies show it only gave 
moderate performance like other non-invasive models. Further validation is needed to 
confirm its clinical significance. Moreover, some models contain markers (i.e. GGT and 
apolipoprotein A l ) that are not included in routine blood test parameters, extra test 
needs to be done and it will increase the test cost, making it less versatile to the public. 
Despite many new non-invasive models were developed and seemed to be 
clinically useful, discrepancies between centers made them inappropriate for clinical 
practice. Diagnostic models using inexpensive biochemical parameters related to liver 
function indeed have its clinical value, more inter-laboratories validation and systematic 
reviews together with standardization of laboratory procedures should be done so that 
these models can be launched for diagnosis. 
Different from direct markers, indirect markers are measures of liver function, 
evaluating the extent of liver injury. Therefore, liver injuries caused by different 
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diseases may perform differently in the same models. Currently available models are 
mainly constructed based on HCV patients. It is necessary to check if the models are 
applicable to other etiologies and evaluate their differences in performance. Some 
publications concerned about the possibility of applying HCV-based models to CHB 
patients as their clinical courses and viral pathologies were different. [50] Patients with 
HBV often have increased ALT level and fluctuated liver enzyme levels while for HCV 
patients, disease progression is slow and silent without fluctuation of liver enzymes. 
Some publications even reported that CHB patients have a greater disease progression 
rate to cirrhosis than CHC patients. [50] It is believed that more evaluation is needed 





































































































































































































































































































































































































































































































































































































Other non-invasive method is imaging. Imaging methods include transient 
elastography (Fibroscan), magnetic resonance imaging (MRI) and contrast 
ultrasonography. [53] Recently, Fibroscan has been evaluated and implemented for the 
assessment of liver fibrosis in many countries. [54] It assesses the presence of liver 
fibrosis by measuring the stiffness of the liver. An ultrasound transducer probe is 
mounted on the axis of a vibrator. The mild amplitudes with low frequency vibrations 
are transmitted by the transducer, inducing elastic shear waves that propagate through 
the tissue. Pulse-echo ultrasound acquisitions can follow the propagation of the shear 
wave and measure its velocity. The velocity is directly related to tissue stiffness; fibrotic 
liver generates higher FibroScan measurement signals measured in kilopascals (kPa). 
Measurements are taken in the right lobe of the liver through the intercoastal spaces. 
This painless and rapid (less than 5 minutes assessing time) method has other 
advantages including immediate result with good reproducibility and more 
representative as sample volume is greater than liver biopsy by at least 100 times. Many 
studies have evaluated the clinical performance of FibroScan with different etiologies of 
CLDs and found that Fibroscan can give fairly stable performance among different 
etiologies. [55] A meta-analysis of Fibroscan showed that it has excellent utility for the 
identification of cirrhosis but large variation of AUROC was found in different liver 
diseases. [56] In France, FibroScan is recommended to be the initial assessment for 
treatment naive CHC patients or patients with no concomitant disorders. [57] Yet, 
Sandrin et al reported that FibroScan was limited to patients with ascites, obese and 
narrow intercoastal space. [58] Liver stiffness measurements are also influenced by ALT 
flares. Chan et al reported that patients with the same fibrosis staging but higher ALT 
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levels are more likely to have higher liver stiffness measurement (LSM). The 
performance of FibroScan is also seriously affected for those patients with low fibrosis 
stage and elevated ALT. Different cut-offs and algorithms were used for definite 
patients groups. [59] Careful evaluation should be done to define a standardized cut-offs 
and algorithms for clinical use. 
Why Proteomics? 
With the completion of human genome project in 2003, surprisingly, it was 
discovered that human had barely more genes than much simpler organisms such as 
roundworm and fly. Human complexity is therefore thought to be contributed by gene 
functions and the way gene products interact, putting a new insight on protein study. [60] 
Considering the biological flow, from DMA to RNA to protein, genome only represents 
the first step of understanding biological functions. It has already an idea that one gene 
to one protein is not hold; there are about 500,000 proteins in human proteome while 
only 40,000 genes are present in human genome, showing that there would be more 
complicated in protein level. [61] In genomics, a moderate correlation was found 
(r=0.61) between protein abundance and mRNA level, indicating that there is a gap 
between the genome sequence and cellular behaviour. It is obvious that genomics cannot 
provide a full answer for biological questions. A new level of gene regulation, 
microRNA (miRNA), was first introduced in 2001，[62] and proteomics may become 
supplement of current work on genomics. More effort should be passed from genomics 
to miRNA and proteomic studies. 
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"Proteomics" is the study of all proteins in a biological system. It provides a 
more realistic view of biological status and therefore is more useful than genomics for 
evaluating diseases. Poor correlation between gene and protein can be explained by the 
differences in the synthesis rate and half-life of mRNA as well as the protein encoded. 
[60] In addition, there are some distinguish advantages on proteomics. Proteomics 
describes dynamic cellular process. It provides information about post-translational 
modifications (PTM) such as glycosylation and phosphorylation which may be essential 
for protein function and activity. The contribution of proteomics is fundamental in 
understanding factors which can alter gene expression but cannot be determined by 
DNA sequence. [63] 
In conclusion, proteins are the core of cellular functions. Study of proteins offers 
researchers the possibility of identifying disease-associated biomarkers for diagnosis, 
prognosis or drug development. 
Clinical values of proteomics in biomarker discovery 
Clinical proteomics aims to discover diagnostic, prognostic and predictive 
biological markers (clinical application) as well as to detect and validate novel drug 
targets (pharmaceutical application). In this regard, proteomics can be classified into 
expression proteomics, functional proteomics and structural proteomics. [64] 
Expression proteomics is the large-scale study of variations in protein expression. 
[60] It is the most popular and expensive proteomics strategy which is analogous to 
differential gene expression. [60] It involves in cataloging proteins expressed in serum, 
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cell or tissue to identify alternations between control and disease samples. Furthermore, 
characterization of the biomarkers has potential to improve patient outcomes. 
Functional proteomics, a specialized form of proteomics, aims to characterize 
protein activities, protein-protein or protein-DNA/RNA interactions and signaling 
pathways. Human genes produce huge amount of proteins via PTMs and mutations 
which can be the sources for examining diseases. Also, a detailed description of the 
cellular signaling pathways can help the elucidation of protein-protein interaction in 
vivo. [65] Unlike expression proteomics, specialized proteins or subproteome are 
isolated for characterization by using affinity chromatography rather than obtaining a 
protein profile to search for differential proteins. More biological functions of proteins 
can be known by understanding the rapid and transient association within large proteins 
complex. 
Structural proteomics aims to elucidate structure-function relationships of 
uncharacterized gene products based on 3D protein structure. It is the deduction of 
biological function from the predicted protein structure. [66] Protein structure can be 
identified by using X-ray crystallography, NMR spectrometry and computational 
method such as comparative and de novo structure prediction. The structural 
information derived from structural proteomics is important in drug development in the 
pharmaceutical industry. 
Challenges in proteomics 
Thousands of proteins per study can be identified in typical mammalian cell but 
it cannot apply to human plasma because of complexity. Much less proteins can be 
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identified in human plasma or serum due to the presence of high abundance proteins. In 
human plasma, the 20 most abundance proteins contribute 99% of the total protein and 
mask the remaining 1% of low abundance proteins which are usually potential 
biomarkers. Large dynamic range of at least 9-10 orders of magnitude in serum 
proteome is the major challenge in clinical proteomics, from the most abundance protein, 
albumin with concentration of 45mg/mL, to low abundance proteins with 1-lOpg/mL. 
[67] Currently there is no publication proposing a proteomics method that can withstand 
a dynamic range of 10 .^ Most of the proteomics technologies have the dynamic range 
limit of 10^. In combination with other advanced separation techniques, the limit can be 
increased to lO* or 10^ Even with the most advanced LC-FTICR technology, the limit is 
still at <10^ which is far from lO'^ showing that current technologies cannot fully 
penetrate into the deep proteome. Many researchers keen to find ways to reduce the 
dynamic range of proteins and the most common way is to deplete those high abundance 
proteins. However, depletion of high abundance proteins may cause reduction of protein 
signals and loss of potential proteins of interest. Liotta et al pointed out that low 
molecular weight (LMW) proteins could stay in blood circulation by binding to large 
carrier proteins. If it is true, existing depletion methods will discard the high abundance 
proteins together with potential biomarkers and fail to capture this valuable resource. [31] 
Many studies used plasma or serum as the starting material. Systematic 
evaluation done by HUPO Plasma Proteome Project (HUPO PPP) showed that about 
40% of all detected signals were unique in serum and cannot be found in plasma. These 
proteins include intracellular, coagulation dependent and enzymatic activity-derived 
peptides. [68] Moreover, it is well known that proteomics is easily subject to sample 
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bias. Proteomic patterns can be changed upon sample collection, processing, storage and 
number of freeze-thaw cycles. HUPO PPP reported that multiple peak differences were 
found in samples stored at freezing, refrigerated (4°C) and room temperature conditions 
for 2 months. [68] Baumann et al also pointed out that unfrozen serum showed great 
variations in protein profiling, giving poor reproducibility. In addition, freeze-thawing 
markedly decreased protein intensities especially in low mass range (m/z 1500-3300). 
[69] Another important issue is the presence of protease in blood samples. No review 
concerning about the origin of proteins or peptides present in blood,- whether they are 
generated in vivo or ex vivo. Marshall et al. illustrated that there were differences in 
proteomic pattern between plasma samples with and without serine-centered protease 
inhibitor, phenylmethylsulphonyl fluoride (PMSF). Serum sample treated with ImM 
PMSF produced an obvious reduction in the high mass range and more peaks were 
observed in the low mass range. Marshall et al concluded that the action of serine 
centered protease contributed to the proteomic profiling pattern ex vivo. [70] However, 
Ayache et al illustrated that the dramatic changes in proteomic pattern is independent of 
protease inhibitor. They demonstrated that protein distribution was altered by the 
processing temperature instead. Remarkable variation of proteins was observed in 
samples left at room temperature for 2 hours and was due to cytokine production and/or 
released by leukocytes and platelets. [71] 
Comparative proteomics is the common strategy used in biomarker discovery. It 
was done by comparing proteomic pattern between disease and control groups. However, 
it is difficult to find a normal applicable to patients with different ages, genders, ethnic 
and menstrual cycles. The "normal" sample is very important in comparative study; it 
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directly influences the interpretation of the proteomics patterns between control and 
disease groups. 
Other challenge is patient heterogeneity, including gender, age, menstrual cycles 
and medications. It is well known that they all contribute changes in proteome patterns 
but no extensive and systematic evaluation was carried out to illustrate how much they 
really affect the proteome content in different patients. This uncertainty hinders the 
development of biomarker discovery. 
Current proteomics technologies in biomarker discovery 
Current proteomics technologies used in biomarker discovery can be classified 
into two categories, gel based and gel-free based approaches. 
Gel based 
Though many chromatographic and electrophoresis-based technologies are 
available for protein separation, two-dimensional polyacrylamide gel electrophoresis (2-
D PAGE), first introduced in 1975, is still the benchmark and routinely used in 
proteomics. [72] The principle of 2-D PAGE is to separate protein mixtures on a gel in 
two dimensions, charges and masses. Proteins are first separated according to their 
isoelectric points (pi) using isoelectric focusing (lEF) and then by their molecular 
weights using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). 
Separated protein spots are visualized by staining the gels with coomassie blue, sliver or 
fluorescent dye such as SYPRO Ruby and Flamingo, depending on the abundance of 
proteins on the gels. [73] The detection limit of different dyes ranges from 0.5 ng to 25 
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ng. SYPRO Ruby and Flamingo show a linear dynamic range over three orders of 
magnitude and have higher sensitivity than others but they need expensive laser-based 
excitation scanner systems for gel visualization whereas coomassie blue has the least 
sensitivity and poor dynamic range. [74] The differential protein spots are then excised, 
destained and performed in-gel digestion with trypsin. After extraction, the peptide 
mixtures are spotted on the target plate and analyzed by Matrix Assisted Laser 
Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF-MS). With the 
use of peptide mass fingerprinting (PMF) and tandem MS technology, the protein 
identity of the protein spot can be obtained with high accuracy. Wang et al used 2-DE 
to investigate the global proteome responses of liver-derived cells to HBV infection and 
treatment response. By comparing two cell lines before and after interferon alpha 
treatment, 6 down-regulated and 11 up-regulated protein spots were identified. 
Identified proteins include vinculin, calumenin and prohibitin. [75] Spano et al. reported 
that 46 differentially expressed proteins were identified in HBV transgenic and 
nontransgenic livers at the early stage of liver fibrosis by 2-D DICE. [76] 
The major merit of 2-D PAGE is that it is capable of separating thousands of 
proteins simultaneously which cannot be achieved by other methods effectively. In the 
first dimension, proteins can be separated in different ranges of pH (i.e. pH 3-10, 3-
lONL, 4-12, 5-8). To increase the resolution in particular pH, narrow pH range or zoom 
lEF can be used. Narrow pH range in lEF is important for avoiding or minimizing spot 
overlapping on the gels, a well-known problem in 2-D PAGE. Large gels using in 
dimension can also increase the resolution dramatically as reported by Wildgruber et al 
[77] However, it is a time-consuming procedure and requires high technical expertise to 
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carry out the separation. In addition, this low-throughput method also greatly suffers 
from gel-to-gel variation, making it unsuitable for comparative proteomics analysis. A 
modified technology, 2-D differential gel electrophoresis (2-D DIGE), was developed to 
increase reproducibility, speed and sensitivity of 2-D PAGE. 2-D DIGE is based on 
measuring three samples on one gel, labeling with different cyanine dyes (Cy2, Cy3 and 
Cy5). By measuring specific wavelength using fluorescent scanner, each labeled 
proteins can be visualized and compared with the other two. It greatly increases 
reproducibility; yet, 2-D DIGE and 2-D PAGE also share limitations that they are not 
applicable for hydrophobic proteins which are insoluble for protein separation. 
Furthermore, proteins with molecular weight less than 5,000 Da cannot be analyzed and 
identified. Due to its low throughput and manually operated nature, gel-free approaches 
have been developed to examine the whole proteome thoroughly and effectively. [78] 
[79] 
Gel free approach - MS based 
Upon 2-D PAGE, mass spectrometry (MS) has gained the popularity and 
become an indispensable tool for proteomics. With the combination of chromatography 
columns and MS, MS based gel free approach can detect many low abundance proteins 
which are usually masked by numbers of high abundant proteins. The primary 
applications of MS to proteomics are cataloging protein expression, defining protein 
interactions and identifying protein interaction sites. [80] Mass spectrometer consists of 
an ion source to ionize the analyte molecules, mass analyzer to separate ionized analytes 
on the basis of mass to charge ratio (m/z) and a mass detector to count the ions at 
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particular m/z value. Currently, two soft ionization techniques, MALDI and electrospray 
ionization (ESI), are widely used for analyzing peptides and proteins. With the use of 
these two ionization techniques, affinity based technologies such as Surface Enhanced 
Laser Desorption/ Ionization (SELDI) and liquid chromatography (LC) become major 
tools in clinical proteomics. 
SELDI-TOF MS 
Surface Enhanced Laser Desorption/ Ionization Time-of-Flight Mass 
Spectrometry (SELDI-TOF-MS) technology was developed by Hutchens and Yip. [81] 
The principle of SELDI technology is similar to classical adsorption-desorption 
mechanism in column chromatography. It is an affinity-based MS technology, 
selectively capturing subset of proteins based on surface chemistries (i.e. hydrophobic, 
ion exchange, metal chelate) or antibodies. [82] This technology enables the analysis of 
small proteins and peptides with mass between 1,000 Da and 20 kDa. It allows direct 
mass spectrometric analysis of the retained proteins/peptides on the array [83] by 
MALDI-TOF MS. Besides capturing low mass of proteins, its non-invasiveness and 
high-throughput manner make it possible for fast screening for novel biomarkers. [84-86] 
It is capable of analyzing wide range of samples such as serum, plasma, cell lysate, 
cerebrospinal fluid [87] and urine. [88] It is an easy, effective and sensitive approach of 
protein profiling for identifying biomarkers especially from crude samples. Its 
sensitivity can be up to femtomolar range. [83] On the other hand, SELDI technology is 
capable of detecting protein variants. A study of renal cancer patients found multiple 
variants of serum amyloid alpha in patient serum but not in healthy control. [89] 
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Jayanthi et al reported that 3 apolipoprotein C-III isoforms were found by SELDI 
ProteinChip and was upregulated in heavy marijuana users. [90] 
As each protein has a unique m/z value and physicochemical properties, they can 
be detected precisely and quantified in patients' fluids using specific ProteinChip arrays 
without knowing their protein identities. However, further characterization of cancer- or 
disease-associated proteomic features not only enables us to understand the disease 
pathology, but also allows us to develop a simple immunoassay to measure potential 
biomarkers. [91] However, the main drawback of ProteinChip SELDI technology is the 
interested protein or potential biomarkers cannot be recovered from the ProteinChip. 
Hence, independent experiment is needed to carry out for protein identification which 
makes the procedures tedious and time-consuming. Protein identification is usually the 
bottle-neck in most of the biomarker studies employing the ProteinChip SELDI 
technology. 
Another drawback, reproducibility, has been controversial in ProteinChip SELDI 
technology. [85] Because sample binding steps in this technology is usually operated 
manually and the serum profiling is sensitive to small changes in the operating 
procedure, large variation between batches or different centers makes this technology 
less reliable. Diamandis pointed out that different patterns and biomarkers were 
identified by various research groups using the same types of biological specimens and 
the same analytical platform. [92] Moreover, hindrance effect occurs during the binding 
reaction as small, information rich proteins needs to compete with large, high abundance 
proteins such as albumin on a small binding surface. Yet this hindrance problem cannot 
be solved by depletion of high abundance proteins. The overall peak intensities were 
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decreased after albumin depletion as reported by Cheng et al. [84] It is believed that 
some albumin-binding proteins were also depleted out with albumin. [93] 
Ward et al showed that two SELDI peaks, identified as K and X 
immunoglopbulin light chains, were up-regulated in patients with hepatocellular 
carcinoma in HCV related cirrhosis. [94] Gogel et al. identified 5 protein markers (m/z 
2,873, 6,646, 7,775, 10,525 and 67,867 Da) to be used to differentiate liver cirrhosis and 
hepatocellular carcinoma in patients with CHC. One protein peak, m/z 6,646, was 
identified as apolipoprotein C-I. [95] -
LC-MS 
An alternate protein separation technology is 1-D or 2-D liquid chromatography 
(1-D or 2-D LC). Its high sensitivity and specificity allows the analysis of biological 
molecules in a complex mixture. LC-MS has become an instrument routinely used for 
protein separation and identification in proteomics laboratory. By using different 
chromatographic columns, whole proteome in biological sample can be fractionated into 
less complex fraction, making it possible for the detection of low abundant protein and 
the deeper proteome. [64] LC-MS is a bottom-up strategy which involves separation and 
digestion of proteins followed by PMF. LC can be linked to different ion sources and 
ion analyzers, providing different platforms for variety uses. Examples of ion sources 
found for proteomics include MALDI, electrospray ionization (ESI), nanospray 
ionization (NSI) and atmospheric pressure chemical ionization (APCI). Ion analyzers 
can be TOF, quadurpole IT (QIT), fourier transform ICR (FT-ICR) and quadruple mass 
filter (QMF). Due to the high complexity of sample, many proteomics studies are 
limited to identify high abundant proteins, those low abundant proteins, potential 
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biomarkers for human diseases, are still the challenge in biomarker discovery. 
Tucholska et al. demonstrated the feasibility of using LC-ESI-MS/MS to identify low 
abundance proteins in complex blood sample. By using multiple partition 
chromatography resins, many polypeptides can be purified to nearly homogeneous from 
serum or plasma samples. Enrichment of low abundance proteins can be achieved by 
depletion of high abundance proteins using custom-designed or commercially available 
depletion columns. [96] Yang et al. demonstrated that after the depletion of HSA and 
IgG, low abundance protein like vitamin-K-dependent clotting factors and inhibitors 
were identified by LC-ESI-MS/MS. [97] Gao et al. also showed that after the depletion 
of 58 high abundance proteins, the number of identified proteins was 2.7 times as that of 
the nondepletion method under LC-MALDI-TOF/TOF MS platform. [98] 
For shotgun proteomics, the multidimensional protein identification technology 
(MudPIT), developed by Yates and colleagues, is now widely implemented to analyze 
complete cell lysates，tissue extracts and other subproteomes. [99] The protein mixtures 
are directly digested into peptides which are then separated by on-line multidimensional 
chromatography followed by tandem mass spectrometric analysis. The digested peptide 
mixtures are separated in strong cation exchange (SCX) column followed by reversed 
phase (RP) column. The eluted fractions are then directly passed into the mass 
spectrometer for protein identification. This system can separate and identify 1,484 
proteins for S. cerevisiae proteome, comprising proteins with extreme pi, MW, 
abundance and hydrophobicity. [100] It is a fast, sensitive method for analyzing 
complex peptide mixtures prior to 2-D PAGE as it is an online process. The main 
drawback is that only one sample can be analyzed in single run, the throughput is low. 
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Furthermore, as digestion is performed before separation of protein mixture, it generates 
a more complex peptide mixture than the original one and makes the separation more 
challenging. In serum, there are at least 200,000 peptides coexist after digestion, 
effective separation on SAX-RP system may not be achieved and more sensitive and 
effective separation technique is needed. [101] Some information may lose upon the 
digestion of proteins to peptides which may result in false identification, especially those 
with diverse or unexpected modifications. In addition, the suppression effect by 
abundance difference in mass spectrometer may restrict the probability of identifying 
medium and low abundance proteins especially when high abundance proteins are co-
eluted with medium and low abundance proteins. More advanced and highly sensitive 
mass spectrometers such as triple quadrupole MS, LTQ FT and LTQ-orbitrap can be 
used to allow more accurate mass measurement and peptide fragmentation schemes. 
Apart from shotgun proteomics approach, a newer strategy known as top-down 
approach was developed for studying intact proteins. This top-down approach does not 
need the purification and digestion of proteins for analysis. It requires high-resolution 
mass measurement of intact proteins and their direct fragmentations with the use of very 
expensive instruments such as Orbitrap or FTICR only. A key to this approach is the 
ability to fragment the intact proteins, it can be performed by using electron transfer 
dissociation (ETD) or electron capture dissociation (ECD) techniques. Using this 
dissociation techniques, small to medium-sized proteins can be fragmented while it is 
incapable of analyzing large proteins (>50kDa) because of increasing complexity 
between the protein ions, tertiary structure and many nonconvalent interactions. It is 
believed that top-down approach can be a tool for sequencing peptides and determining 
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the post-translational modification sites which cannot be done by bottom-up approach. 
[102] [103] However, since it is performed with a single protein or simple protein 
mixture fractionated off-line, the analytical throughput and efficiency for large-scale 
proteome analysis is still a challenge. Recently, Bryan et al. demonstrated proof-of-
concept for high throughput top-down proteomics made from the measurement of high-
resolution MS/MS fragment ions in an online fashion. [104] With the integration of 
offline weak anion exchange (WCX) column and online LC-LTQ FT, 22 proteins were 
identified on yeast whole cell lysate. -
1.3.4.3 Quantitative proteomics 
The major progress in proteome study is quantitative proteomics. It is important 
to obtain quantitative information from healthy and disease group for biomarker 
discovery. Stable isotope and molecular labeling methods are currently used for 
quantitative proteomics. Because the labels are chemically identical, the peptide pair 
(light and heavy peptides) will behave identically in terms of chromatographic retention 
and ionization efficiency, allowing samples to be analyzed and compared 
simultaneously. 
Stable isotope labeling by amino acids in cell culture (SILAC) is a common 
stable isotope labeling technique used in cell culture. [105] Two populations of cells are 
cultivated in different culture medium. One of the populations is fed by stable isotope-
labeled essential amino acids while the other is fed by normal one. The stable isotope 
will then be absorbed and secreted by cells in the synthesis of proteins in vitro. '^C is 
usually chosen for labeling, and '^Ce lysine is labeled in HCC cell lines with low 
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and high metastatic potentials for quantitative analysis respectively. [106] Peptide pair 
was separated by 6 Da corresponding to the mass difference between and 
isotopes.By measuring their intensities ratio, differential proteins can be found and 
identified. Nearly all peptides can be isotopic labeled by SILAC, greatly improving the 
sequence coverage of proteins. However, it is not practical for clinical protein samples 
in vivo. 
Isotope-coded affinity tag (ICAT) was introduced in 1999 by Aebersold and co-
workers. [107] The ICAT reagent consists of a reactive group specific for free thiol 
functionality of cysteine residues, a polyether linker region with deuteriums or '^C with 
their light forms (i.e. 'H and '^C) and a biotin tag that allows recovery of labeled 
peptides. In ICAT experiment, the light and heavy isotopic tags bind covalently to 
cysteine moieties of amino acids within proteins. The proteins are then eluted from an 
avidin column and quantified with MS. The relative amount of the identified peptides 
can be calculated by the ratio between heavy and light forms. Because only cysteine-
containing peptides are isolated, complexity of the sample will not affect quantitative 
analysis and it allows detection of low abundance peptides. This technology has been 
applied to study proteome in mammalian cells and human liver cells. Yet, many 
important proteins which do not have cysteine cannot be detected. [108] About 300-400 
proteins per sample can be analyzed by ICAT, far less than that with 2-D PAGE 
technology. Also, deuterium affects peptide retention time in LC and intense fragment 
ions from biotin moiety makes the complicated MS/MS spectra not suitable for database 
searching. 
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Isobaric tag for relative and absolute quantization (iTRAQ) is increasingly 
accepted in secretome analysis. iTRAQ labels consist of reactive groups label with all 
free amines, at the N-terminus of all peptides and also the side chain of internal lysine 
residues, a balance group and a reporter group . [109] Unlike ICAT, they target all 
tryptic peptides and therefore enhance the depth of the coverage. There are currently two 
types of reagents: 4-pIex and 8-plex. Each label has an identical mass but produces 
different fragments during collision-induced fragmentation in MS/MS analysis. Mixed 
differentially labeled peptide mixtures at equimolar concentration, separated by 2-D 
chromatography and subjected to tandem MS/MS analysis, a special mass signal at m/z 
114.1, 115.1, 116.1 and 117.1 can be obtained from the fragmentation between the 
reporter and balance groups. Each signal correlates directly to the amount of peptides 
present in the sample, thus protein concentration can be deduced. [110] The advantage 
of iTRAQ technology is that different tags will not affect the separation performance 
which makes it possible for analyzing at least four samples in single run. However, it 
suffers from some limitations. Fragmentation efficiency depends on charge and 
sequence, small amount of co-eluted labeled fractions may have similar m/z fragment 
ions that can lead to significant error in reporter ion distribution. 
The MS-based technique of multiple reaction monitoring (MRM) is now being 
explored for validation of protein biomarkers in clinical samples. It is not a new 
technique for small molecules which has been used for quantification of metabolites in 
drug metabolism studies over 30 years. Due to the emergence of new MS 
instrumentations, MRM is now capable of analyzing large molecules such as proteins 
and peptides. [ I l l ] For low molecular weight analysis, triple quadrupole mass 
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spectrometer enables the precursor ion (parent ion) to be selected in the first quadrupole, 
followed by fragmentation by collision with inert gas atom in the second quadrupole and 
finally passed to the third quadrupole for analyzing selective fragment ion (daughter ion). 
In principle, this technique is able to confirm the identity of the precursor ion by 
fragment ion in a specific transition. Moreover, in combination of stable isotope-labeled 
internal standards (SISs), absolute quantitation can also be obtained. [112] For protein 
and peptide analysis, a triple quadrupole-linear ion trap (QqQ-LlT) instrument like Q 
TRAP® has advantages. Q TRAP® has a high sensitivity that is able to detect low 
abundance analytes in complex matrices. Several recent proof of principle studies 
showed that MRM can be identified and quantified proteins at ng/mL level. Keshishian 
et al showed that 6 spiked proteins in immunodepleted human plasma can be 
quantitated in the 1-lOng/ml range with coefficient of variation ranges from 3 to 15%. 
[113] Kay et al also demonstrated that in combination with ACN precipitation, insulin-
like growth factor-I (IGF-I) can be detected in MRM experiment which has the 
concentration of lOOng/mL in human serum. [114] Besides, Q TRAP® is able to switch 
rapidly between triple quadrupole and linear ion trap mode, making it possible to carry 
out MRM-initiated detection and sequencing (MIDAS). MIDAS, first developed for the 
identification of phosphorylation site on the yeast cell cycle proteins, consists of 
standard M R M experiment and a full-scan product ion to confirm the identity of the 
parent ion, especially for peptide post-translational modifications. [115] Positive MRMs 
trigger an MS/MS experiment to confirm the nature and modification site. It is a more 
sensitive approach due to efficient duty cycle and reduced background signal. Although 
M R M technique shows promising result in the quantitation limit, it still faces lots of 
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limitations that hinder the development of this technique. Detection of low abundance 
proteins which is always masked by high abundance proteins remains the main 
challenge for MRM. It remains unclear the potential of MRM to detect and quantify 
trace amount of protein in a "sea" of high abundance proteins which cover about 99% of 
the total protein. Though there are several depletion methods for enrichment of low 
abundance proteins, it showed that depletion couldn't increase the number of peptide 
transition detected. [116] In addition, designing and validating individual peptide 
transition is a major bottleneck of MRM. In silico methods are available to derive the 
possible MRM transition based on the theoretical rules and empirical observation of the 
target peptide, however, Anderson et al showed that by using in silico method to derive 
peptide transition, only 11 of 30 proteins were identified, indicating that in silico method 
is not reliable enough for transition determination. [116] 
1.3.5 Applications of proteomics to discovery of biomarkers for diagnosis of liver 
fibrosis 
Only few studies used SELDI ProteinChip technology to find biomarkers for the 
detection of HBV-associated liver fibrosis or cirrhosis. Zhu et al. found two markers, 
7,772 and 3,933 m/z, for detection of HBV-induced liver cirrhosis using SELDI 
technology. Two markers were found to be down-regulated in liver cirrhosis group. The 
decision tree model achieved good accuracy (80% sensitivity and 81.8% specificity) 
with 75% positive predictive value. [117] Another study conducted by Cui et al., two 
differential protein peaks (2,050 and 3,166 m/z) were found for detection of CHB with 
100% sensitivity and 86.5 % specificity. [118] Poon et al. reported 30 protein features 
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together with several routine laboratory parameters were included in artificial neural 
network (ANN) model. With a cut-off of 3.0, the ANN model attained good accuracy 
(96% sensitivity, 89% specificity) for detecting liver fibrosis. [119] Though these 
studies reported models with good diagnostic accuracy in their study group, the 
identities of these protein markers were still unknown and the calculation of these 
models were so complicated for clinical use. 
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Rationale and Objectives of the Project 
There is a lack of sensitive and specific serum markers for diagnosis of liver 
fibrosis. Our recent pilot study showed that serum proteomic fingerprint identified by 
the ProteinChip SELDI technology might allow diagnosis of liver fibrosis in CHB 
patients with high accuracy. Unfortunately, the non-recovery nature of the ProteinChip 
SELDI prohibited the identification of the proteomic features forming the diagnostic 
fingerprint. Hence it was important to develop a new technology comparable to the 
ProteinChip SELDI, but it allows purification of the proteins corresponding to the 
proteomic features in parallel. 
The objectives of this research project are: 
1 To develop a magnetic beads-based proteomic profiling method for quantitative 
proteomic profiling and micro-purification in parallel; 
2 To develop a proteome-based fingerprinting model for detecting liver fibrosis in 
patients with chronic hepatitis B infection 
3 To uncover the protein identities of proteomic features forming the diagnostic 
fingerprint 
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Section 1 Method development of magnetic beads-based proteomic 
profiling for quantitative proteomic profiling and micro-purification in 
parallel 
1.1 Introduction 
High throughput quantitative serum profiling method is a useful tool for 
biomarker discovery and is a potential blood test for disease diagnosis/prognosis. By 
comparative proteomic approach, new disease- associated biomarkers can be discovered 
for clinical use. 2-D PAGE was a traditional technique used in biomarker discovery. 
Though it can effectively separate hundreds to thousands of proteins on the gel, low 
throughput and lack of reproducibility are still the main limitations on 2-D PAGE which 
makes it unsuitable for high throughput screening. 
In the past 10 years, there was an overwhelming interest in using SELDI 
technology in biomarker discovery. It is a variant of MALDI-TOF MS used to retain a 
subproteome on the functionalized affinity surface. Proteins retained on the SELDI chip 
are then directly analyzed by MALDI-TOF MS to generate a proteomic profile. By 
using statistics methods, differential proteomic features can be found for the underlying 
diseases. Though biomarker can be reproducibly detected and quantified by the SELDI 
technology even not knowing the protein identity, for clinical use, knowing the protein 
identity is indispensable so that the protein-protein interaction or disease pathologies can 
be understood. The main drawback of the SELDI technology is the retained proteins 
cannot be recovered for further protein identification and analysis. Independent time-
consuming small-scale chromatography needs to be performed to purify the 
corresponding proteins for subsequent protein identification work. Protein identification 
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is usually the bottle-neck in most of the biomarker studies employing the ProteinChip 
SELDI technology. In addition, there are several limitations of the SELDI technology, 
for example, high cost, high susceptibility to identify false-significant biomarkers due to 
systemic bias and sensitive to small changes of experimental procedures and analytical 
variables. [120] Also, competition between large and small proteins occurs during 
sample binding on a small chromatographic surface. 
On the other hand, instrument performance plays an indispensable role in 
quantitative serum profiling. The instrument sensitivity greatly affects the possibility of 
detecting low concentration of proteins on the spot. In addition, stable instrument 
performance can give reproducible MS spectra, reducing variations during MS analysis. 
In this section, we aimed to develop a magnetic bead-based proteomic 
fingerprinting method which was comparable to ProteinChip SELDI technology, but 
allowed quantitative proteomic profiling and microscale purification of the profiled 
proteins in parallel. The performance of the instrument, reproducibility of the proteomic 
profile and the feasibility of protein identification of the MS peak were examined. 
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1.2 Materials and methods 
1.2.1 Biological specimen 
Blood was collected from a healthy volunteer with consent. The blood was 
clotted at room temperature for 30 minutes, and centrifuged at 3000xg for 15 minutes. 
The serum was stored in 10 |liL aliquots at -80 °C before analysis. 
1.2.2 Automated platform for protein capture with magnetic beads 
To improve reproducibility and achieve a high throughput, the capture 
procedures were automated by using the KingFisher 96 magnetic particle processor 
(ThermoFisher), which could process 96 samples per run. Figure I showed the 
schematic diagram of the whole magnetic bead-based serum profiling procedure. 
1.2.3 Capture of hydrophobic serum proteins 
serum was diluted and inactivated with 198|xL of binding buffer (0.9% 
sodium chloride (NaCl) containing 0.1% trifluoroacetic acid (TFA)). 0.5 mg of C18 
magnetic beads in 10 ^L (Dynabeads RPC18, Invitrogen) were pre-washed sequentially 
with 90|liL of pure acetonitrile (ACN) and lOO^iL of binding buffer. 80|liL of diluted 
serum samples were mixed with the washed C I8 beads for 10 minutes. The C I8 beads 
were then washed 3 times with lOO^L of 0.2% TFA. Finally, the captured proteins were 
eluted with 60|liL of universal elution solution (50% ACN containing 0.2% TFA). 
1.2.4 Capture of anionic serum proteins 
2^iL serum was first denatured by adding 8|iL of UC buffer (9M Urea, 2% 
CHAPS, 2.5mM Tris-base, lOmM Tris-HCl). After incubation at room temperature for 
30 minutes, the denatured serum samples were diluted with 190^L of pH 8 phosphate 
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binding buffer (20 mM sodium phosphate, 30% ethanol, pH 8.0). 0.5 mg of SAX 
magnetic beads in 10 [iL (Dynabeads SAX, Invitrogen) were mixed with 60|iL of 1.5 M 
NaCl and 30 |xL of ethanol for prewashing, and then washed with 100 ^L of pH 8 
phosphate binding buffer. SOjiL of diluted serum samples were mixed with the washed 
SAX beads for 10 minutes. The SAX beads were then washed with pH 8 phosphate 
binding buffer, followed by 3 washes with washing buffer (2.3^M ethanolamine, 30% 
ethanol, pH 9.0). Finally, the anionic proteins were eluted with 60|iL of universal elution 
solution. • 
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MS analysis Protein Identification 
Figure 1. Schematic diagram of the magnetic bead-based serum proteomic profiling method for parallel 
analytical analysis and micropreparative purification. In the C I 8 assay, serum was diluted and inactivated 
with 0.9% NaCl containing 0.1% TFA; in the SAX assay, the serum was denatured with urea-CHAPS 
(UC) buffer. All the binding and washing procedures were performed automatically with a 96-sample 
magnetic particle processor. 
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1.2.5 Evaluation of the performance of linear MALDI-TOF MS 
The performance of PCS 4000 ProteinChip reader (Bio-Rad Laboratories) was 
evaluated by using ProteinChip OQ Kit (Bio-Rad Laboratories). Unless specified, all 
testing peaks were selected on the spectra and peak information was exported and pasted 
on ProteinChip SELDI OQ form for calculation. ProteinChip detector qualification array 
was used to test the detector sensitivity of PCS 4000 ProteinChip reader. Two different 
concentrations (lOfmol and MOfmol) of immunoglobulin (IgG) were analyzed and the 
corresponding signal-to-noise ratio (S/N) was measured. 1 of 1 partition was used for 
MS analysis. For high concentration, it passed if S/N was greater than 1,000. For low 
concentration, it passed if S/N was greater than 5. ProteinChip peptide standard array 
was used for mass drift, resolution and mass accuracy tests. 1 of 4 partitions was used 
for MS analysis for these three tests. Mass drift and resolution was measured on insulin 
peak (5.96 kDa). It passed if the mass drift was less than 7 Da and average resolution 
was greater than 750. Resolution was further assessed on arg-8-vasopressin peak (1.08 
kDa). It passed if the resolution was greater than 1,000. Mass accuracy of the system's 
internal and external calibration was tested on arg-8-vasopressin (1,084.247 Da), 
somatostatin (1,637.903 Da), dynorphin A (2147.5 Da), ACTH (2,933.5 Da), beta 
endorphin (3,465 Da), arg-insulin (5,963.8 Da) and cytochrome C (12,230.92 Da). For 
external calibration, it passed if the average mass within 0.1% of calibrant mass and 
pooled CV of <0.05. For internal calibration, it passed if the average mass with 0.01% 
of calibrant mass and pooled CV of <0.01. 
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1.2.6 Quantitative serum proteomic profiling by linear MALDI-TOF MS 
l|aL of eluate was spotted onto an 8-spot gold ProteinChip array (Ciphergen 
Biosystems) in duplicate. 0.5|xL of sinapinic acid matrix (13mg/mL sinapinic acid 
dissolving in 50% ACN/ 0.5% TFA) (Sigma-aldrich) was added by using of nano-liter 
non-contact dispenser (BioDot AD3050) and air-dried in a chamber with humidity 
control at 80%. Another 0.5灿 of sinapinic acid matrix was added and air-dried. The 
gold ProteinChip array was subjected to the PCS4000 ProteinChip reader (Bio-Rad 
Laboratories) to determine the masses and intensities of all the peaks over the m/z range 
from 1,000 to 250,000 m/z. Two acquisition protocols were used for low and high mass 
ranges. Intensities of peaks between 1,000 and 20,000 m/z were obtained at a laser 
power of 6,000nJ and the focus mass was 8,000 m/z; intensities of peaks between 
10,000 to 250,000 m/z were obtained at a laser power of 10，000nJ and the focus mass 
was 80,000 m/z. The mass spectra were externally calibrated with a mixture of 
peptide/protein standards (angiotensin, 1,296.51 m/z; ACTH (clip 1-17), 2,093.46 m/z; 
ACTH (clip 18-39)，2465.72 m/z; double charged horse apomyoglobin 8475.8 m/z; E. 
coli Thioredoxin, 11673.5 m/z, horse apomyoglobin, 16951.6 m/z; bovine serum 
albumin, 66430 m/z; bovine serum albumin dimer, 132861 m/z) (Applied Biosystems). 
The common peaks among the mass spectra were identified and quantified using the 
Biomarker Wizard software (Bio-Rad Laboratories). The peak intensities were 
normalized with the total ion current, and subsequently with the total peak intensities. 
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1.2.7 Reproducibility analysis of magnetic bead-based protein spectra 
The peaks with normalized intensities > 0.15% of total peak intensities were 
used to evaluate the reproducibility of magnetic bead-based mass spectra. Same serum 
sample was subjected to quantitative proteomic profiling in at least 20 replicates in a 
single experiment for assessing the intra-assay (i.e. within assay) error. For assessing 
interassay (between assays) error, same serum sample was subjected to quantitative 
proteomic profiling for at least 15 times on different days. For each peak, the intra-assay 
and interassay coefficients of variation (CVs) of the normalized - intensities were 
calculated according to the standard formula (CV = standard deviation / mean value). 
1.2.8 Non-reducing 2-D gel electrophoresis 
Eluted protein sample was dried at 45 using speedvac concentrator 
(Enppendorf) and reconstituted with ISS^iL of rehydration buffer (8M Urea, 2% CHAPS, 
0.2% Biolyte 3-10 ampholyte, 0.001% bromophenol blue, ImM EDTA). An 
immobilized pH gradient (IPG) strip (11cm 3-lONL, Bio-Rad Laboratories) was 
rehydrated with the sample overnight. For the first dimension lEF separation, the 
running condition was as follows: lOOV for lOmin, 250V for 65min, 500V for 25min, 
lOOOV for 40min, and finally 8000V for MOmin. Second dimension SDS-PAGE was 
performed on 4-12% Bris-Tris po 1 yaery 1 amide gels (Bio-Rad Laboratories) and the 
proteins were separated at 200 V for 40min in ice bath. The 2D gel was then stained 
with silver nitrate using Amersham PlusOne silver staining kit (GE Healthcare) with 
some modifications to reduce the loss of proteins with MW < 10 kDa. The gel was fixed 
in 40% methanol/10% acetic acid for 30 min and then sensitized by thiosulfate solution 
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with 25% w/v Glutardialdehyde. Washed with 30% ethanol for 15 min, the gel was 
immersed with silver solution in 30% ethanol and 37% w/v formaldehyde for 1 hr. The 
gel was washed with Milli-Q water for Imin for 3 times and then developed in sodium 
carbonate solution with 37%w/v formaldehye. The development was stopped by EDTA 
solution and the gel was rinsed with Milli-Q water for 3 times before performing image 
analysis with GS-800 calibrated densitometer (Bio-Rad Laboratories). 
1.2.9 Protein identification of eluted proteins 
Protein spots were excised from silver stained gels. The gel pieces were 
destained, reduced with 1.75% DTT, alkylated with 350 mM lAA, and digested with 
modified porcine trypsin overnight (Sequencing grade modified typsin from Promega, 
Madison, WI). The tryptic digest was harvested and cleaned up with CI8 ZipTips 
(Millipore). The cleaned tryptic peptides were subjected to MALDI-TOF/TOF MS 
(Applied Biosystems 4700 Proteomic Analyzer, Applied Biosystems) with a-cyano 4-
hydroxy cinnamic acid as matrix. The MS and MS/MS spectra were then processed with 
Data Explorer software (Ver. 4.4; Applied Biosystems). The spectra were subjected to 
gaussian smoothing with a filter width of 5 points, and the baselines were corrected with 
default settings. Peaks were detected based on a S/N > 15. The MS spectrum data were 
searched via the online ProFound search engine to obtain the protein identity by 
undertaking the peptide mass fingerprinting (PMF) approach. Tandem MS data were 
subjected to MS/MS ion search via the Mascot search engine to obtain the protein 
sequence of a particular peptide. For the search parameters, the 1 missed cleavage in 
trypsin digestion was allowed; partial oxidation of methionine, phosphorylation of 
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serine/threonine/tyrosine, and iodoacetamide modification of cysteine residues were 
selected. The error tolerance values of the parent peptides and the MS/MS ion masses 
were 200ppm and 0.5 Da, respectively. A protein identification result was considered 
valid when both PMF and MS/MS ion search identified the same protein as the 
statistically significant hit from the NCBInr database, and/or when MS/MS ion search 
identified at least tryptic peptides with sequences from the same protein as the 
statistically significant hits. 
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1.3 Results 
1.3.1 Serum proteome profiles obtained with different types of chromatographic 
magnetic beads 
Two different assays for profiling hydrophobic proteins and anionic proteins were 
successfully developed by using CI8 and SAX magnetic beads respectively. Different 
chromatographic magnetic beads resulted in different proteomic profiles (Figure 2 and 
3). CI8 hydrophobic beads captured more proteins in m/z 2000-8000 range than SAX 
beads. Peak at m/z 2750 was unique in CI8 assay. However, there was an exception in 
this range. Proteins at m/z 6,400 and 6,600 had greater affinities in SAX, giving 1.5 to 2 
times of the signal intensities compared with the hydrophobic condition. There was also 
a unique peak found in the SAX profiling assay at m/z 13,850 which cannot be found in 
C18 profiling assays. However, in high mass range, there was no obvious peak 
difference between the two profiles. The only difference was SAX beads captured the 
proteins in greater amount than C18 beads; the overall intensities from SAX profile were 
about 5 times greater than that of C18 beads. 
For the CI8 profiling assay, 88 peaks (74 peaks with normalized intensities > 
0.15% of total intensities) between 1,600 m/z and 20,000 m/z and 143 peaks (93 peaks 
with normalized intensities > 0.15%) between 20,000 m/z and 250,000 m/z were 
observed. For the SAX profiling assay, 65 peaks (54 peaks with normalized intensities > 
0.15%) between 1,600 m/z and 20,000 m/z and 74 peaks (46 peaks with normalized 
intensities > 0.15%) between 20,000 m/z and 250,000 m/z were observed. 
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Figure 2. Representative proteomic profiles obtained with different bead types at low mass range (1,000-
20,000 m/z). Top: CI 8 beads; Bottom: SAX beads. 
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Figure 3. Representative proteomic profiles obtained with different bead types at low mass range (10,000-
250,000 m/z). Top: C I8 beads; Bottom: SAX beads. 
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1.3.2 Performance of PCS 4000 ProteinChip reader 
All performance tests were passed. For detector sensitivity test, the average S/N 
for 140 fmol and 10 fmol were 1147.37 and 51.26 respectively. For mass drift and 
resolution test at 5.96 kDa, the mass drift and resolution were found to be 2.94 and 
817.67 respectively. For resolution at 1 kDa, the resolution was 1681.91. For external 
and internal calibration, the average mass of the calibrants was within 0.03% and 0.01% 
and the pooled CV was 0.023 and 0.005 respectively. Figures 4 - 7 showed the 
resulting spectra of each test. -
49 
100000 125000 150000 175000 
3 ‘ “ 
、 1 I 13fl010217a_»pt>uCl71 
0 “ ^ . —• 
0.06 ^ 1 5 2 3 8 0 6 5 
^ 二 y 卜 则 咖 - 吸 , 1 1 
勺 I /fl 卿 _ ‘ ‘ 
, 1 】 , , 
0 5 L 
0.06 
< 0.04 J Nv I • , 
0,02 y ‘ 
% "t l3SD10217a.*potO,1 ] 
0.5 一 ^ ^ ^ ^ 一 
0 J ~ 产 J ^ 3 。 
0,025 
Q ‘ , 
% 1 [ 13fl0102178_»poiG_1.1 1 
0 ‘ "^ - — . ^ 
,6 1 ° 加 , , 
% 0.04 / v . [ 13gnrei7»_ipem.l 1 1 
0 ^ 
100000 125000 150000 175000 
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1.3.3 Reproducibility of magnetic beads-based serum proteomic profiling 
The reproducibility of each profiling assay was assessed in terms of coefficients 
of variation of the normalized intensities of the protein peaks. The intra- and inter-assay 
CVs for the 2 assays were summarized in Table 2. The reproducibility of the 2 assays 
was similar, but it appeared that the SAX assay had the best performance. The 
normalized intensities of peaks at higher m/z range appeared to be more precise. The 
intra-assay and interassay CVs of different peaks within a proteomic profile were similar, 
and both in the range of 4 to 30%. Figures 8 and 9 showed representative spectra for the 
reproducibility of this magnetic bead-based approach. 
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Table 2. Reproducibility of quantitative proteomic profiles by using CI 8 and SAX beads. Intra-assay and 
interassay coefficients of variation (CVs) of the normalized intensity of each MS peak were calculated, 
and mean values of the CVs from multiple peaks were presented, 
api - number of replicates 
bThe peaks were ranked from the highest normalized intensities to the lowest. 
Intra-assay CV, % Interassay CV, % 
Bead type Mass range mean ( m i n : - m a x . � mean (min. - max ) 
n® ToplQb 11 丨 h_20th i f Top 10 1广-20"^ 
C18 1600-20,000 m/z 24(18-29)24(15-30) 25 (21-30)""“26(13-30) 
20 16 
20,000 - 250,000 m/z 14(8-21) 22 (14-30) 18(15-22) 20(14-29) 
SAX T2T6^)~ 一 “ " 2 4 ( 1 8 - 3 0 ) 
24 24 
20,000 - 250,000 m/z 8(4-17) 8(6-13) 14 (7-19) 16(10-22) 
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Figure 8. Representative spectra obtained with C18 beads. Top: High molecular range (m/z 20,000-
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Figure 9. Representative spectra obtained with SAX beads. Top: High molecular range {m/z 20,000-
250,000) Bottom: Low molecular range {m/z 1000-20,000) 
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1.3.4 Gel electrophoresis of the eluted proteins 
50% ACN solution containing 0.2% TFA was successfully developed as the 
universal elution solution regardless of the types of functionalized magnetic beads used. 
Because it is a volatile solvent, it can be easily removed by speed vac. Then the dried 
proteins could be redissolved in any appropriate solvents for subsequently gel 
electrophoresis. The eluted proteins could be separated by non-reducing 2D PAGE for 
the ease of subsequent protein identification (Figure lOA). 
1.3.5 Identification of the protein peaks 
The protein identities of the protein spots in a 2D PAGE can be obtained by 
undertaking standard methods employing MALDI-TOF/TOF MS. The protein peaks in 
the mass spectrum could be easily matched with the protein spots with similar molecular 
weight to obtain their identities. Figure IOC is a typical example illustrating the proteins 
identified in the proteomic profile from a normal healthy subject, which were consistent 
to results previously reported by our team and by other teams using the SELDI 
ProteinChip technology for biomarker discovery. For example, the m/z 11685 peak were 
found to be serum amyloid A, which was consistent to what we found in a previous 








































































































































































































































































































































































































































It is believed that low abundance and small proteins (< 15kDa) of the serum 
proteome contain important diagnostic information and should be a rich source of 
undiscovered biomarkers. However, tradition techniques like 2D PAGE, only allows the 
separation and quantification of proteins with molecular weight in a range of 10 to 
300kDa. [122] Lots of valuable diagnostic information may be lost if the sample is 
subjected to 2D PAGE analysis. This limitation has been overcome by the invention of 
the ProteinChip SELDI technology. However, low reproducibility and not applicable for 
protein identification hinders its development in biomarker discovery. 
To overcome the problems faced by the ProteinChip SELDI technology, magnetic 
bead-based quantitative serum profiling method was developed in the present study. An 
automatic platform was used to process different types of chromatographic magnetic 
beads, such as hydrophobic CI8 beads and strong cation exchange beads, to capture and 
release serum/plasma proteins with specific physicochemical properties. One microliter 
of the eluted proteins (60 uL) was directly spotted on a gold ProteinChip array in 
duplicate, overlaid with sinapinic acid, and finally subjected to the ProteinChip reader of 
SELDI-TOF MS system for acquiring the quantitative proteomic profile (i.e. mass 
spectrum), while the rest of the eluate was enough for subsequent protein identification 
experiments. The resulted proteomic profiles can be analyzed with existing informatic 
softwares for SELDI-TOF MS experiments. This method is cost effective, and can be 
easily adopted by those laboratories equipped with a SELDI-TOF MS system. 
The performance of magnetic bead-based method was comparable to the 
ProteinChip SELDI technology. Different types of ProteinChip arrays could produce 
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different proteomic profiles. Similarly, the use of different types of magnetic beads 
produced different proteomic profiles. Different profiles from CI8 and SAX beads 
illustrate that combined use of different magnetic bead-based profiling assays can obtain 
a more comprehensive proteomic profiles for biomarker discovery. C I8 beads were 
functionalized with CI8 alkyl groups which were hydrophobic in nature. It was used for 
reversed phase fractionation of complex protein/peptide mixtures. It was believed that 
the major proteins captured from CI8 beads were mainly hydrophobic proteins. As most 
proteins are hydrophobic due to long carbon chain, C I8 beads would than give a global 
profile for protein analysis. SAX beads were functional ized with strong anion exchanger 
which was used to adsorb anionic proteins. By using optimized pH (i.e. pH 8) for 
binding, proteins with their pi values below 8 would become negatively charged and 
captured on the magnetic beads. Washing steps were introduced to wash away any 
contaminants and non-specific binding proteins. The pH of the washing solution was 
prepared to have one pH unit above the binding solution (i.e. pH 9) to ensure only 
negatively charged proteins were adsorbed. This greatly enhances the specificity of the 
protein profile. This can explain why more peaks were found in C I8 protein profile and 
some unique peaks were found in either protein profile. With the combination of CI8 
and SAX profiling assays, proteins with different properties were captured and more 
information can be obtained for protein analysis. 
Instrument performance was important for acquiring good quality of mass spectra 
for further analysis. The detector sensitivity, resolution, mass drift and mass accuracy 
were the main factors affecting the quality of the mass spectrum. Failure in any one of 
these may cause wrong peak clustering or failure in detecting low abundance protein 
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peaks for data analysis. The performance of the PCS 4000 ProteinChip reader was 
evaluated using OQ kit (Bio-Rad Laboratories). All tests including detector sensitivity, 
mass drift, resolution and mass accuracy were passed, indicating the MALDI-TOF MS 
was in good condition for acquiring MS spectra for proteomic profiling. The detector 
sensitivity test showed that protein can be detected at lOfmol level with S/N greater than 
5. It showed the MALDI-TOF MS was sensitive enough for detection of low abundance 
proteins which were believed to be potential biomarkers. A severe mass drift may cause 
wrong peak clustering for data analysis which would led to make erroneous conclusion 
on the results. Mass drift of the spectra was therefore important to be evaluated. The 
mass drift between spectra was found to be negligible (2.94 Da) and wrong peak 
clustering was not likely occurred. Moreover, if the resolution of the MALDI-TOF MS 
was not good enough, proteins with similar molecular weight would merge to form one 
single peak, reducing protein peaks detected in the whole profile. The resolution at 1 
kDa was high even 3 other peaks were very close to the testing protein, arg-8-
vasopressin. The result showed that PCS 4000 ProteinChip reader was capable of 
detecting peak proteins with similar masses with high resolution. Mass accuracy was 
important in identifying the interested proteins in the spectra. External and internal 
calibration was carried out to ensure the experimental mass did not deviate too much 
with the theoretical mass. The result showed that the experimental mass was close 
enough with the theoretical mass. 
The reproducibility of peak intensities of magnetic bead-based profiling assays 
(both intra-assay and interassay CVs in range of 4 to 30%) was comparable to the values 
reported for the ProteinChip SELDI technology. [123][124] Alteroviz et al reported an 
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intra-assay CV of 28% for automatic procedure and an intra-assay CV of 45% when 
done manually. [123] Using a robotic sample-processing station, Semmes et al reported 
an intra-laboratory CV from 9 to 43%. [124] In the present study, the use of the 
automated magnetic particle processor for processing the magnetic beads and serum 
samples was one of the keys to achieve good reproducibility. Another automated 
machine used was the nano-liter non-contact dispenser for adding matrix chemical on 
the gold ProteinChip arrays, and the matrix drying step of the added matrix were well 
controlled in a humidity control chamber. It was found that amount of matrix added and 
the drying time could greatly affect the reproducibility. The use of automated machines 
helped to reduce assay-to-assay and person-to-person variations. This also explained 
why the intra-assay CVs and the interassay CVs of assays were very close. 
In addition, reproducibility is greatly governed by binding step which depends on 
the quality of the chromatographic surface. Compared with ProteinChip arrays, the 
functionalized magnetic beads can be manufactured in large single batch and distributed 
to different laboratories while the ProteinChip arrays have to be made one by one. 
Therefore, the quality of magnetic beads can be more easily controlled. 
Protein identification was done to demonstrate the feasibility of the magnetic bead-
based approach to obtain enough eluted proteins for both MS analysis and protein 
identification in one capture step. In contrast, the ProteinChip SELDI technology 
required additional samples and additional preparative purification steps to obtain 
protein fractions that were similar to those captured on the ProteinChip arrays. 
Another advantage of this profiling method is that magnetic bead-based assays are 
more sensitive than the ProteinChip-based SELDI assays. The binding capacity of 
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magnetic beads is much higher than that of ProteinChip arrays. Furthermore, the 
capability of a magnetic bead-based assay can be easily increased by using more 
magnetic beads. In this method, the magnetic beads were added in excess to avoid 
competition among the serum proteins for the binding sites, which happened in the case 
of ProteinChip SELDI technology. Study showed that the ProteinChip SELDI 
technology yielded fewer mass peaks than a profiling assay based on magnetic beads 
and MALDI-TOF MS using urine samples. [125] 
1.5 Conclusion 
A magnetic bead-based proteomic profiling method was successfully developed. It 
was comparable to ProteinChip SELDI technology, but allowed quantitative proteomic 
profiling and microscale purification of the profiled proteins in parallel. The resulted 
proteomic profiles can be analyzed with existing informatic softwares for SELDI-TOF 
MS experiments. It is a good alternative to ProteinChip SELDI technology for 
biomedical research. 
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Section 2 Development of a proteome-based fingerprinting model for 
detecting liver fibrosis in patients with chronic hepatitis B infection 
2.1 Introduction 
Liver fibrosis is the wound-healing scar due to liver injury such as chronic liver 
diseases. It can progress from liver fibrosis, cirrhosis and ultimately liver cancer. The 
prevalence of hepatitis B infection varies worldwide and the highest rates are seen in 
Asia. Each year, an estimated 500,000 people die of cirrhosis and liver cancer caused by 
chronic infection. CHB adult patients develop liver cancer at a rate of 5 % per decade 
which is approximately 100-fold higher than the rate among non-infected people. [126] 
Liver fibrosis is a reversible and appropriate treatment may reverse the liver 
fibrosis and prevent further complications. Clinical guidelines published by the 
American Association for the Study of Liver Diseases in 2007 recommended that 
patients with HBV DNA > 20,000 lU/mL and persistently or intermittently elevated 
ALT with age greater than 40 should be evaluated by liver biopsy. [127] Liver biospsy 
is the gold standard to ascertain the degree of liver injury. The main role of liver biopsy 
is to assist in deciding the need for antiviral therapy. Although antiviral treatment 
suppresses the viral replications effectively, complete eradication of HBV infection is 
rarely achieved with current available therapies. [128] Therefore, treatment monitoring 
is important to evaluate the treatment efficacy and consider the endpoint of therapy. Feld 
et al further pointed out that liver fibrosis was perhaps a stable marker for disease 
progression. However, liver biopsy is subject to sampling error and its invasive nature 
makes it impossible for repeated measurements. 
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Blood tests based on the biochemical and virological markers maybe more 
appropriate for treatment monitoring due to its non-invasiveness. Current blood tests 
such as FibroTest and hepascore have good accuracy for diagnosis of liver fibrosis and 
cirrhosis with an area under the ROC curve -0.8. [129][130] 
The formation of liver fibrosis causes disruption of liver architecture and loss of 
liver function. As proteins are mainly synthesized by liver, alternation of protein 
contents between disease and control groups may reflect the progression of liver disease. 
Blood is a good reservoir of proteins. It is believed that differential serum proteins can 
be found between disease and control groups by using comparative approach. Serum 
proteomic profiling is a useful tool in comparative proteomics and has been widely 
applied to biomarker discovery in different diseases such as breast cancer [131], liver 
cancer [132] and esophagus cancer. [133] 
Serum proteomic profiling can be obtained using 2-D PAGE and gel-free mass 
spectrometry-based technologies, such as ProteinChip SELDI technology. By 
comparing the protein spot intensities in the 2D gel images between disease and control 
groups, differential spots were excised for protein identification. White et al. identified 7 
differential proteins using 2-D PAGE/LC MSMS platform in a CHC-associated liver 
fibrosis study. [134] However, it is a time consuming procedure and subject to large gel-
to-gel variation which limits the sample size of the study. Gel-free mass spectrometry-
based technology was then served as an alternative for biomarker discovery. 
Certain protein markers were found to be associated with HBV-related liver 
fibrosis and cirrhosis using SELDI technology. [117-119] Serum protein markers may 
reflect not only liver function and inflammation but also other physiologic conditions of 
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liver fibrosis. Diagnostic models were constructed based on the differential protein 
markers. Though these reported models achieved good correlation with liver fibrosis 
(ROC curve area >0.8)，the unknown protein identities and complex diagnostic models 
made them less applicable for clinical use. 
In addition, most studies used treatment naive samples to construct diagnostic 
models, but seldom assess the accuracy of the diagnostic model using post-treatment 
samples. The accuracy of the model in detecting liver fibrosis after antiviral treatment 
remains unclear. Only treatment-independent diagnostic model can be used in treatment 
monitoring. For example, acute phase response proteins markers identified by SELDI-
TOF technology may not be useful in treatment monitoring as they can be easily altered 
by antiviral treatment. [135] In addition, hematologic abnormalities may occur after 
antiviral treatment. [126] As some of the current non-invasive diagnostic models consist 
of biochemical and hematological parameters, the accuracy of them may be affected. 
Further examination on these models using serum/plasma samples that were collected 
after the antiviral treatment should be done to assess the possible use in treatment 
monitoring. 
In this section, we aimed to identify the serum proteomic fingerprint, and 
develop a diagnostic model for the detection of liver fibrosis in patients with CHB 
infection using the magnetic bead-based proteomic fingerprinting approach developed in 
the first part of this M.Phil, study. The diagnostic model was validated in a second 
independent group of serum samples that were collected after antiviral treatment to 
investigate the its possible use in treatment monitoring. 
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2.2 Materials and methods 
2.2.1 Patient materials 
The current study included patients with CHB who were recruited or screened 
for other therapeutic trials as well as patients who were suspected of having active liver 
disease based on laboratory or radiologic investigations between 1998 to 2005 in the 
Prince of Wales Hospital, Hong Kong. All patients had compensated liver disease at the 
time of recruitment. Patients had received combined treatment of peginterferon and 
lamivudine, lamivudine or placebo treatment during the study period. Patients had 
received antiviral treatments for 1 year, and liver biopsy were collected 6 months after 
the termination of treatment. After obtaining informed consent, fasting blood samples 
were collected by venipuncture and liver function tests were carried out within 4 weeks 
prior to liver biopsy. All patients had been fasting for at least 6h before the blood 
sampling. Serum was stored at -80°C before proteomic profiling analysis. Clinical, 
biochemical and hematological data were recorded from each patient. Hematological 
and biochemical parameters (complete blood screens, coagulation tests, bilirubin, total 
protein, albumin, AST, ALT, alkaline phosphatase (ALP)) were measured by a Modular 
Analytic system (Roche Diagnostics). All patients gave written consent for use of these 
data for research purposes and use of these clinical samples for biomarker discovery was 
approved by the university ethics committee. 
Liver biopsies were obtained with 16-gauge Temno needles (Bauer Medical). 
The specimens were fixed with formalin, embedded in paraffin, and stained with 
hematoxylin-eosin. Liver tissues were at least 1.5cm in length with a minimum of five 
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portal tracts for diagnosis. Histological staging of liver fibrosis was assessed using Ishak 
fibrosis score by a single pathologist blinded for the clinical and proteomic data. 
A total of 214 randomly selected serum samples (104 treatment naive, 110 post-
treatment) were used in this study. 102 patients had both pre- and post-treatment 
samples; 2 patients had pre-treatment samples only and 8 patients had post-treatment 
samples only. 
Pre-treatment serum samples were used for construction of diagnostic models 
using magnetic-based proteomic profiling technology and post-treatment samples were 
used for independent validation, to examine the independence of the model upon anti-
viral therapy. 
2.2.2 Serum proteomic profiling 
Serum samples were analyzed by two types of magnetic beads, C18 and SAX, to 
capture hydrophobic and anion proteins respectively. An automated machine, Kingfisher 
96，was used for protein extraction in 96-well format for single run. The experimental 
conditions were briefly described. For C18 condition, serum was diluted and 
inactivated with 198|LIL of binding buffer (0.9% sodium chloride (NaCl) containing 
0.1% trifluoroacetic acid (TFA)). 0.5 mg of C18 magnetic beads in 10 ^iL (Dynabeads 
RPC18, Invitrogen) were pre-washed sequentially with 90)aL of pure acetonitrile (ACN) 
and lOO^iL of binding buffer. SO^iL of diluted serum samples were mixed with the 
washed C I8 beads for 10 minutes. The C I8 beads were then washed 3 times with 100|LIL 
of 0.2% TFA. Finally, the captured proteins were eluted with 60|iL of universal elution 
solution (50% ACN containing 0.2% TFA). For SAX condition, 2\iL serum was first 
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denatured by adding 8|LIL of UC buffer (9M Urea, 2% CHAPS, 2.5mM Tris-base, lOmM 
Tris-HCl). After incubation at room temperature for 30 minutes, the denatured serum 
samples were diluted with 190|iL of pH 8 phosphate binding buffer (20 mM sodium 
phosphate, 30% ethanol, pH 8.0). 0.5 mg of SAX magnetic beads in 10 ^iL (Dynabeads 
SAX, Invitrogen) were mixed with 60)iL of 1.5 M NaCi and 30 |iL of ethanol for 
prewashing, and then washed with 100 |LIL of pH 8 phosphate binding buffer. 80|NL of 
diluted serum samples were mixed with the washed SAX beads for 10 minutes. The 
SAX beads were then washed with pH 8 phosphate binding buffer, followed by 3 
washes with washing buffer (2.3|xM ethanolamine, 30% ethanol, pH 9.0). Finally, the 
anionic proteins were eluted with 60)iL of universal elution solution. 
2.2.3 Quantitative serum proteomic profiling by linear MALDI-TOF MS 
1|LIL of eluate was spotted onto an 8-spot gold ProteinChip array (Ciphergen 
Biosystems) in duplicate. 0.5)iL of sinapinic acid matrix (13mg/mL sinapinic acid 
dissolving in 50% ACN/ 0.5% TFA) (Sigma-aldrich) was added by using of nano-liter 
non-contact dispenser (BioDot AD3050) and air-dried in a chamber with humidity 
control at 80%. Another 0.5^L of sinapinic acid matrix was added and air-dried. The 
gold ProteinChip array was subjected to the PCS4000 ProteinChip reader (Bio-Rad 
Laboratories) to determine the masses and intensities of all the peaks over the m/z range 
from 1,000 to 250,000 m/z. Two acquisition protocols were used for low and high mass 
ranges. Intensities of peaks between 1,000 and 20,000 m/z were obtained at a laser 
power of 6,000nJ and the focus mass was 8,000 m/z; intensities of peaks between 
10,000 to 250,000 m/z were obtained at a laser power of 10，000nJ and the focus mass 
was 80,000 m/z. The mass spectra were externally calibrated with a mixture of 
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peptide/protein standards (angiotensin, 1,296.51 m/z; ACTH (clip 1-17), 2,093.46 m/z; 
ACTH (clip 18-39), 2465.72 m/z; double charged horse apomyoglobin 8475.8 m/z; E. 
coli Thioredoxin, 11673.5 m/z, horse apomyoglobin, 16951.6 m/z; bovine serum 
albumin, 66430 m/z; bovine serum albumin dimer, 132861 m/z) (Applied Biosystems). 
The common peaks among the mass spectra were identified and quantified using the 
Biomarker Wizard software (Bio-Rad Laboratories). The peak intensities were 
normalized with the total ion current, and subsequently with the total peak intensities. 
The duplicate normalized peak intensity measurements were averaged for further 
statistical analysis. 
2.2.4 Statistical analysis 
Serum samples were divided into two groups. Treatment naive samples were 
used as training group for both biomarker discovery and diagnostic model construction 
and post-treatment samples were used as validation group. The correlations among Ishak 
score, protein peak intensities obtained from magnetic bead protein profiles, age 
(calculated to the date of liver biopsy), circulating HBV DNA, haemoglobin level (HB), 
white blood cell count (WBC), platelet count (PLT), INR, total protein concentration, 
albumin concentration, bilirubin concentration, ALP, AST and ALT were analyzed by 
Spearman's rank correlation test. Mann-Whitney U and bivariate Spearman's rank 
correlation tests were conducted with SPSS 16.0 (SPSS, Inc, Chicago, IL). 
For the discovery dataset, 4 criteria should be fulfilled for a differential 
proteomic features. Firstly, the normalized protein peaks should be significantly higher 
or lower in patients with significant fibrosis than those patients without significant 
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fibrosis. 2-independent sample comparison tests were performed by using Mann-
Whitney U test. 2 groups were classified based on Ishak scores, Minimal fibrosis (Ishak 
score = 0，1 and 2) and typical fibrosis (Ishak score = 4，5 and 6) groups. Secondly, the 
normalized protein peaks should be associated with the progression of liver fibrosis. 
Spearman's rank correlation test was used to examine the correlations between 
proteomic features/serological parameters and the degrees of liver fibrosis. Thirdly, the 
proteomic features should be identified to be significantly associated with Ishak score at 
a false discovery rate (FDR) less than 5%. To assess the FDR, significance analysis of 
microarray (SAM) analysis was used (Stanford University, 161, 162). In the SAM 
analysis, "Quantitative" was selected in response type list, “ranks” was chosen in 
regression method, and 5,000 permutations were performed. Fourthly, the differential 
proteomic features should be significantly correlated with at least 1 of the 
serological/biochemical/clinical parameters to illustrate its biological relevance. 
Proteomic features showed statistically significant in all 4 tests were considered as 
potential biomarkers. 
2.2.5 Development of diagnostic model 
The potential proteomic, biochemical and serological markers were log2 
transformed before constructing diagnostic model. The log： values were subjected to 
multiple linear regression (forward stepwise) to formulate predictive models for 
detecting significant liver fibrosis. During model training, the potential proteomic, 
biochemical and serological markers were used as independent variables and Ishak score 
as dependent output variable. For the biomarker discovery group, the performance of the 
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predictive model was evaluated by 10 fold cross-validation. Briefly, all treatment naive 
cases were divided into 10 groups, the model was trained on 9 groups and the trained 
model was then used to test the case that had been left out. The process repeated until 
every case in the dataset had been used once as an unseen test case. The results were 
averaged across all cases to evaluate the prediction performance. Receiver Operating 
Characteristic (ROC) curves was used to assess the sensitivity and specificity of the 
diagnostic models in detecting significant fibrosis (Ishak score >2) and cirrhosis (Ishark 
score >4). The positive (PPV) and negative predictive values (NPV) were then 
calculated to investigate the diagnostic value of the predictive model. 
2.2.6 Independent validation of diagnostic model 
Independent validation was carried out using post-treatment data to evaluate the 
accuracy of the predictive model and examine whether the model was affected by 
antiviral therapy. The diagnostic value of the model was assessed by ROC curve 
analysis, and sensitivity, specificity, PPV and NPV in detecting significant fibrosis were 
calculated according to standard equations. 
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2.2.7 Comparison of the constructed diagnostic model with other non-invasive 
models 
Two non-invasive models constructed for detecting CHB associated liver fibrosis, 
Aspartate aminotransferase to platelet ratio index (APRI) [Hepatology 2003，38，518-26] 
and age-platelet index (API) [J Viral Hepatol 1997;4:199-208], were investigated, and 
their diagnostic performances were compared with our predictive model. APRI and API 
were calculated according to the following equation and procedure. 
Equation for calculating APRI: 
ADDi AST level/ULN ，，湖 
APRI = , , ^ 令 、 X 100 
Platelet counts (10 /L) 
Procedure for calculating AP index: 
1) Age (years): <30=0; 30-39 =1; 40-49 =2; 50-59 =3; 60-69 = 4; >70 =5 
2) Platelet count (10^/L): >225 =0; 200-224=1; 175-199 =2; 150-174 =3; 125-149 =4; <125 =5 
3) AP index is the sum of the age-platelet count index (possible value 0-10) 
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2.3 Results 
2.3.1 Patient characteristics 
For pre-treatment group, the mean (SD) of Ishak fibrosis score was 1.81 (1.55). 
10 patients had no fibrosis (Ishak score =0); 52 had minimal fibrosis (Ishak score =1); 
23 had mild fibrosis (Ishak score =2); 8 had moderate fibrosis (Ishak score =3 or 4); 6 
had severe fibrosis (Ishak score =5), and 5 had probable/ definite cirrhosis (Ishak score 
=6). The prevalence of significant fibrosis in discovery group was 18.27%. 
For post-treatment group, the mean (SD) of Ishak fibrosis score was 1.84 (1.76). 
14 patients had no fibrosis (Ishak score =0); 61 had minimal fibrosis (Ishak score =1); 9 
had mild fibrosis (Ishak score =2); 11 had moderate fibrosis (Ishak score =3 or 4); 7 had 
severe fibrosis (Ishak score =5), and 8 had probable/ definite cirrhosis (Ishak score =6). 
The prevalence of significant fibrosis in validation group was 23.64%. Minimal fibrosis 
was defined as Ishak score lower than 3 while significant fibrosis was defined as Ishak 
score greater than 3，indicating the presence of bridging fibrosis and/or cirrhosis. Table 3 
showed the distribution of fibrosis stages in both pre- and post-treatment groups. Results 
showed that the prevalence of significant fibrosis was similar in both training and 
validation groups. 
The demographic data of pre- and post-treatment groups were compared to find 
any differences in biochemical/ hematological data after antiviral treatment using two-
tailed Student-t test. To avoid multiple comparisons, p-value was adjusted using 
Bonferroni method and p <0.003 was considered as statistically significant. There were 
no significant difference in age, Ishak score, HB, WBC, PLT，INR, total protein and 
bilirubin concentration (p-values > 0.003). On the other hand, statistically significant 
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differences were found in PT, ALB, ALP, AST, ALT and HBV DNA. All these 
parameters except ALB were found to have lower level in post-treatment groups. 
Further evaluation was done on pre- and post-treatment dataset. The serum 
samples from patients with and without significant liver fibrosis were separated and 
investigated to evaluate the effects of the treatment on the serological/biochemical 
parameters. For patients without significant fibrosis, PT, INR, ALB, ALP, AST, ALT 
and HBV DNA were found to be statistically significant between pre- and post-
treatment groups (p-values < 0.003). For patients with significant fibrosis, ALB, AST 
and ALT were significantly different between pre- and post-treatment groups (p-values 
<0.003). All the comparisons in different groups were summarized in Tables 4-6. 
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Table 3 Distribution table of patients with different Ishak scores in pre- and post-treatment samples. 
N.A.= Not applicable 
Pre-treatment I Post-treatment “ 
Ishak score samples samples Pe r�=age 
(n=104) (Zo) (n=110) (,。） 
0 10 ^ 14 一 12.73 
1 — 52 50.00 61 55.45 
— 2 23 22.12 9 8.18 
3 — 2 1.92 4 3.64 
— 4 6 5.77 7 “ 6.36 
5 — 6 5.77 7 — 6.36 
一 6 — 5 4.80 8 •• 7.27 
— Mean 1.81 N.A. — 1.84 “ N.A. 一 
— SD 1.55 N.A. - 1.76 N.A. 
Prevalence of ^ 18.27 26 ^ 
significant Fibrosis 
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Table 4 A summary of demographic data of all patients in pre- and post-treatment samples, mean 
(SD) (*p <0.003) N.A = Not applicable 
Pre-treatment Post-treatment 
M ^ P - v — 
~Sex (Male/Femai^ 3.00 3.07 N.A. 
Age (yr) — 35.8 (10.0) 37.90(10.5) 0.136 
Ishak score 1.81 (1.55) 1.84 (1.76) a900 
一 HB (g/L) 14.83 (1.49) 14.86(1.55) 0 . 8 6 7 ~ 
WBC (107L) 6.45 (5.53) 6.18 (1.65) 0.633 — 
— P L T ( 1 0 ^ / L ) 一 183.51 (54.28) 203.79 (60.27) . “ 0.011 
PT (sec) — 11.07(0.83) “ 10.45 (0.64) "<0.0005* 
INR 一 1.07(0.08) _ 1.04 (0.07) 0.004 
"Total protein (g/L) 76.83 (4.53) “ 77.75 (5.03) ~~0.163 
ALB (g/L) 39.93 (3.20) 43.95 (3.21) <0.0005* 
Bilirubin (mg/dl) 10.42 (4.33) [ 1 1.35 (5.37) 0.165 
ALP (lU/L) 87.90 (24.84) 74.00 (22.79) <0.0005* 
AST (lU/L) 80.82 (51.27) _ 31.42 (21.17) "<0.0005* 
ALT (lU/L) 一 151.73 (103.48) 51.94 (59.04) ~ ^ 0 0 0 5 * 
— H B V D N A 5.71E+08(1.01E+09) I 4.84E+06 (1.91E+07) <0.0005* 
78 
Table 5 A summary of demographic data of patients with minimal fibrosis in pre- and post-treatment 
samples, mean (SD). (*p <0.003) N.A = Not applicable 
Pre-treatment I Post-treatment 
Minimal fibrosis Minimal fibrosis P-value 
Sex (Male/Femai^ 2.70 2.74 N.A. 
Age (yr) 34.69 (9.99) 35.92 (9.84) 0.424 
Ishak score 1.15 (0.61) 0.94 (0.52) 0.016 
HB (g/L) — 14.76(1.48) 14.66(1.63) 0.694 
WBC (107L) 一 6.52 (6.05) 6.40 (1.68) 0.863 
一 P L T ( 1 0 ' / L ) 一 191.96 (52 .78) 215.38 (58 .09) . ~ ~ 0 . 0 0 7 
— P T (sec) 10.93 (0.79) 10.28 (0.51) "<0.0001* 
— INR 1.07(0.08) 一 1.03 (0.05) — <0.0001*— 
"T^tal protein (g/L)— 76.79(4.82) — 77.94 (4.62) 0 . 1 14~ 
ALB (g/L) 40.22 (3.31) 44.08 (3.16) ~^.0001* 
Bilirubin (mg/dl) 9.98 (4.38) 10.69 (5.55) 0.354 
ALP (lU/L) 86.07 (24.19) 71.08 (21.08) <0.0001* 
一 AST (lU/L) 75.08 (48.44) — 30.54 (20.93) _ <0.0001* 
一 ALT (lU/L) — 149.93 (105.09) 48.70 (57.92) ~^.0001* 
HBVDNA 6.68E+08 (1.08E+09) 3.68E+06 (1.71E+07) <0.0001* 
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Table 6 A summary of demographic data of patients with significant fibrosis in pre- and post-treatment 
samples, mean (SD). (*p <0.003) N.A = Not applicable 
Pre-treatment Post-treatment 
Significant fibrosis Significant fibrosis P-value 
~Sex ( M a l e / F e m a ^ 5.33 5.00 N.A. 
Age (yr) 40.74 (8.48) 44.31 (10.36) 0.225~~ 
Ishak score 4.74(0.99) 4.73 (1.08) 0.985 
一 HB (g/L) — 15.14(1.55) 15.50(1.04) 0 . 3 4 7 ~ 
~ ~ W B C (1 07L) — 6.09(1.99) 5.46(1.36) — 0.212 
PLT jlOVh) 145.68 (44.88) 166.35 (52.22) . 0.172 一 
PT (sec) 一 11.68 (0.77) 11.01 (0.70) ~ 0 . 0 0 4 
INR — 1.12(0.08) — 1.11(0.07) 0.560~~ 
"Total protein (g/L) 77.00 (3.04) 77.11 (6.22) ~~0.941 
ALB (g/L) 38.63 (2.31) — 43.54 (3.42) "<0.0001* 
Bilirubin (mg/dl) 12.42 (3.52) — 13.50 (4.12) 0.362 
ALP (lU/L) 96.11 (26.72) 83.42 (25.84) 0.116 
AST (lU/L) 一 110.00 (53.24) 36.31 (22.72) "~0.001* 
一 ALT (lU/L) 一 159.79 (98.24) 62.38 (62.52) ~0.001* 
HBVDNA 1.49E+08 (3.14E+08) | 1.27E+07 (2.94E+07) 0.144 
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2.3.2 Correlation between biochemical/serological markers and the degrees of 
liver fibrosis 
4 significant serological markers (PLT, PT, bilirubin and HBV DNA level) were 
correlated with the degrees of liver fibrosis. PLT and HBV DNA were negatively correlated with 
the degrees of liver fibrosis while PT and bilirubin were positively correlated. List of differential 
serological/biochemical markers were summarized in Tables 7 and 8. 
2.3.3 Serum proteomic profiling by linear MALDI-TOF MS 
Protein profiles were obtained in two mass ranges, low (1,000 and 20,000 m/z) and high 
mass range (10,000 to 250,000 m/z). In CI8 profiles, 129 and 74 peaks were found in low and 
high mass range respectively. In SAX profiles, 69 and 81 peaks were found in low and high 
mass range respectively. 
2.3.4 Correlation of proteomic features with Ishak score 
5 differential proteomic features were associated with Ishak scores and 
significantly different in minimal and significant fibrosis groups. At a FDR < 5%, 4 of 
the differential proteomic features (9,165, 9,452, 10,045 and 12,243 m/z) were found 
from CI8 profiles and one (17,286 m/z) was from SAX profiles. Among 5 potential 
proteomic markers, 3 (9,165, 9,452 and 12,243 m/z) were down-regulated and 2 (m/z 
10,045 and 17,286) were up-regulated. List of differential proteomic features were 
summarized in Table 9. Representative spectra of individual peaks were shown in 
Figures 11-14. 
81 
Table 7 List of significant differential proteomic features (p <0.05, FDR<5%), mean (SD) 
Correlation ^ ^^alue Minimal Significant 
coefficient Spearman Mann- fibrosis fibrosis 
correlation Whitney U 
PLT -0.399 <0.0005 <0.0005 191.96 (52.78) 145.68 (44.88) 
PT 0 .349 " ~ ^ . 0 0 0 5 0.001 "“~IO.93 (0 .79) “ 11.68 (0 .77) 
Bilirubin 0.255 0 . 0 0 9 ~ 0.005 9.98(4.38) 12.42 (3.52) 
^ Q 6.67E+08- 1.49E+08 
DNA -0.369 0.002 0 .額 (1.08E+09) (3.14E+09) 
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Serological markers (r, p-value) 
WBC (0.255，0.009)，PT (-0.288，0.003)，INR (-0.311, 0.003)，Bilirubin (-0 212 
PLT ‘ 
0.03)， 
PLT (-0.288, 0.003)，INR (0.882, <0.0005), Bilirubin (0.325, 0.001), ALP 
PT 
(0.320,0.001), AST (0.339，0.002)，HBVDNA (-0.257, 0.033) 
HB (0.236，0.016), PLT (-0.212, 0.03)，PT (0.325, 0.001)，INR (0.327, 0.002), ALT 
Bilirubin 
(0.200，0.042)，AST (0.297，0.008) 
HBV D N A P T (-0.257, 0.033) ‘ 
Table 8 A summary of correlation of biochemical / serological markers (p <0.05) 
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Table 9 List of significant differential proteomic features (p <0.05, FDR <5%), mean (SD) 
Correlation p-'^ aluQ Minimal Significant 
coefficient Spearman Mann- fibrosis fibrosis 
correlation Whitney U 
- 0 . 2 ^ 0 . 0 0 4 0.045 0 . 0116 ( 0 . 0047 ) 0 .0096(0 .0036) 
m/z 9452 ~~^324 0.001 0.025 0.0141 (0.0069)飞.0106 (0.0049)一 
" i ^ l 0 0 4 5 0.248 0 . 0 1 1 0 . 0 4 1 0.0235 (0.0105) 0.0282 (0.0123) 
1 ^ 1 2 2 4 3 -0.317 0.001~~ 0.02 0.0044 (0.0027) 0.0032 (0.0017) 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2.3.5 Correlation of significant proteomic features with serological markers 
4 significant proteomic features were correlated with serological markers. 
9,165 m/z was positively correlated with WBC (r = 0.200, p = 0.042). Two proteomic 
features, 10,045 and 12,243 m/z were associated with clotting factors. Proteomic feature 
10,045 m/z, which was up-regulated with the degree of liver fibrosis, was negatively 
correlated with PLT (r = 0.228, p = 0.02) and positively correlated with PT (r = 0.240, p 
=0.015). 12,243 m/z, a down-regulated marker, was negatively correlated with PT (r =-
0.208，p = 0.035) and INR (r = -0.223, p = 0.034) and positively correlated with PLT (r 
=0.228, p = 0.02). The correlation between proteomic features and serological markers 
were summarized in Table 10. These 4 proteomic features were then regarded as 
potential diagnostic markers. 
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Table 10 A summary of correlation of significant proteomic fearures and biochemical / serological markers (p 
<0.05) 
Proteomic 
Serological markers (r, p-value) 
feature 
m/z9165 WBC (0.200, 0.042) 
m/z 10045 PLT (-0.227，0.021), PT (0.240，0.015), “ 
m/z 12243 PLT (0.228, 0.02), PT (-0.208, 0.035), INR (-0.223，0.034)， ~ 
m/z 1 7 2 8 6 P L T (-0.183,0.013) 
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2.3.6 Construction of diagnostic model in detecting liver fibrosis and cirrhosis 
A total of 8 log2 of normalized potential protein markers and serological markers were 
selected to construct linear regression model (forward stepwise). Two protein markers 
(9,165 and 12,443 m/z) and PT were selected as the independent variables in the 
diagnostic model. The linear regression model was found to be Proteomic fibrosis index 
=-0.739*log2 (peak intensity of m/z 9165) - 0.398* log2 (peak intensity of m/z 12443) + 
3.689* log2 (PT) -19.09. For predicting liver fibrosis (Ishak score >2), the diagnostic 
model was useful in identifying cases with significant liver fibrosis in the CHB patients 
with AUROC = 0.758 (95% CI 0.640-0.875, p = 0.0005). At a high cut-off of 2.4693, 
the specificity and sensitivity were 88% and 42% respectively. At a low cut-off of 
1.5294, the specificity and sensitivity were 48% and 90% respectively. For predicting 
liver cirrhosis (Ishak score > 4)，the diagnostic model was useful in identifying cases 
with significant liver cirrhosis in the CHB patients with AUROC = 0.851 (95% CI 
0.743-0.958，p < 0.0005). At a high cut-off of 2.4693，the specificity and sensitivity 
were 88% and 64% respectively. At a low cut-off of 1.9762, the specificity and 
sensitivity were 66% and 91% respectively. 
2.3.7 Cross-validation of the diagnostic model using pre-treatment samples in 
detecting liver fibrosis and cirrhosis 
After 10 fold cross-validation, the diagnostic model showed similar performance. 
Our predictive index was consistent with Ishak score with a good correlation (r = 0.452, 
p < 0.0005) and a positive trend was shown in the boxplot. [Figure 15] 
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For predicting liver fibrosis, the diagnostic model was useful in identifying cases 
with significant liver fibrosis in the CHB patients with AUROC = 0.726 (95% CI 0.605-
0.846，p < 0.005)，indicating overfitting did not significantly exist in the predictive 
model. With the use of high (3.0844) and low cutoffs (1.3068)，the PPV and NPV were 
found to be 80% and 96% respectively. 
For predicting liver cirrhosis, the model was significantly useful with AUROC = 
0.825 (95% CI 0.709-0.941，p<0.0005). With the use of high (3.0844) and low cutoffs 
(1.8981)，the PPV and NPV of detection of liver fibrosis were found to be 80% and 98% 
respectively. Figure 15 showed a summary of ROC curves for both discovery and cross-
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Figure 15 Boxplot of the predictive index in pre-treatment group (Group 1: minimal fibrosis (Ishak score 
=0，1,2); Group 2: moderate fibrosis (Ishak score = 3，4); Group3: cirrhosis (Ishak score = 5,6)) 
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Figure 16 ROC curves of the diagnostic models in detecting significant fibrosis and cirrhosis in discovery 
group (pre-treatment). A) Liver fibrosis B) Liver cirrhosis C) 10 fold cross-validation for liver fibrosis D) 
10 fold cross-validation for liver cirrhosis 
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2.3.8 Independent validation of the diagnostic modd using post-treatment 
samples in detecting liver fibrosis and cirrhosis 
Post-treatment samples protein data was used to evaluate the independence of the 
diagnostic model to the anti-viral therapy. Our predictive index was consistent with 
Ishak score with a good correlation (r = 0.211’ p < 0.05) and a positive trend was shown 
in the boxplot. [Figure 17] 
For liver fibrosis, the diagnostic model was useful in identifying cases with 
significant liver fibrosis in the CHB patients with AUROC = 0.750 (95% CI 0.640-0.860, 
p < 0.0005)，similar to the performance in the pre-treatment discovery group. For 
predicting liver cirrhosis, the diagnostic model was useful in identifying cases with 
significant liver cirrhosis in the CHB patients with AUROC = 0.783 (95% CI 0.672-
0.894, p < 0.0005). Figure 18 showed the ROC curves of the diagnostic model in 
detecting liver fibrosis and cirrhosis. Same cutoffs were obtained in predicting fibrosis 
and cirrhosis with the same accuracy. With the use of high (2.7303) and low cutoffs 
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Figure 17 Boxplot of the predictive index in post-treatment group (Group 1: minimal fibrosis (Ishak score 
=0，1,2); Group 2: moderate fibrosis (Ishak score = 3，4); Group3: cirrhosis (Ishak score = 5,6)) 
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Figure 18 ROC curves of the diagnostic models in detecting significant fibrosis and cirrhosis in validation 
group (post-treatment). A) Liver fibrosis B) Liver cirrhosis 
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2.3.9 Comparison against other non-invasive models in detecting liver fibrosis 
and cirrhosis 
The diagnostic performances of two non-invasive models, APRI and API, and 
our diagnostic model were compared. Our predictive model showed comparable results 
with the APRI and API models. For pre-treatment samples, both APRI and API models 
were useful in identifying cases with significant liver fibrosis in the CHB patients with 
AUROC = 0.791 and 0.781，respectively (p values=0.001). However, for post-treatment 
samples, the APRI model was not significantly useful in predicting post-treatment 
samples while API was still significantly useful (p=0.045). However, the AUROC of the 
API was dropped from 0.781 to 0.676. Our predictive model showed better and more 
stable performance in detecting post-treatment samples with an AUROC of 0.750. 
Proteomic model (m/z 9,165 and 12443) was constructed and compared with our 
reported diagnostic model (m/z 9，165，12443 and PT). The linear regression model was 
found to be Proteomic index = -0.827*log2 (peak intensity of m/z 9,165) - 0.513* log2 
(peak intensity of m/z 12,443) 一7 . 833 . For predicting liver fibrosis (Ishak score >2), the 
diagnostic model was useful in identifying cases with significant liver fibrosis in the 
CHB patients with AUROC = 0.676 (95% CI 0.546-0.807，p = 0.017). However, the 
proteomic model was not significantly useful in predicting post-treatment samples (p-
value >0.05). Figure 19 and Table 11 showed the ROC curves and comparison of the 
diagnostic accuracy between our diagnostic model, proteomic model, APRI and API 
using pre-treatment data respectively. Figure 20 and Table 12 showed the ROC curves 
and comparison of the diagnostic accuracy between our diagnostic model, proteomic 
model, APRI and API using post-treatment data respectively. 
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Figure 19 ROC curves of constructed diagnostic model, proteomic model, APRI and API models using 
pre-treatment samples. 
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Table 11 A comparison of AUROC of different non-invasive models using pre-treatment samples. (*p 
<0.05) 
、T . . , , a T 1 95 % confidence interval 
Non-invasive model AUROC p-value — . Tr ； — 
Lower bound Upper bound 
Our diagnostic model 0.726 0.002* 0.605 0.846 
Proteomic model “ 0.675 0.017* — 0.545 0.806 
— APRI 0.791 ~~0.001* 0.676 ~ 0.907 — 
— API 0.781 0.001* 0.638 0.925 一 
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Figure 20 ROC 
curves of constructed diagnostic model, APRI and API models using post-treatment 
samples. 
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Table 12 A comparison of AUROC of different non-invasive models using post-treatment samples. (*p < 
0.05) 
95 % confidence interval 
Non-invasive model AUROC p-value Lower~~ ~ “ ~~ 
bound Upper bound 
“Our diagnostic model 0.750 <0.0005* 0.640 0.860 
Proteomic model —0.621 0.066 0.500 0.743 
— APRI ~0.633 0.130 0.439 0.827 
API 0.676 0.045* 0.471 0.880 
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2.4 Discussion 
Currently there is no drug that can cure liver fibrosis directly though it is thought 
to be a reversible process. Antiviral therapy is mainly taken by patients with chronic 
hepatitis diseases to suppress or clear the virus load level so that the stress on the liver 
can be relieved and allow recovery on the fibrosis area. Several drugs were approved by 
the U.S. FDA and taken by patients with different treatment responses. In our study, 
patients were taken combined treatment of peginterferon and lamivudine, lamivudine or 
placebo treatment. Similar clinical trials studies [136-138] showed that decrease of PLT 
occurred during the anti-viral treatment, indicating the host responses might be affected 
by the medication. In our study approach, post-treatment samples were included and 
therefore a systematic evaluation on the serological parameters was done to investigate 
the effect of the antiviral treatment which might affect the diagnostic accuracy of the 
non-invasive models. 
Recently, there were 3 studies using SELDI technology to find biomarkers in 
detecting HBV-associated liver fibrosis. [117-119] Though the recruited patients had the 
same etiology, different differential proteomic features were reported. There are two 
reasons for this discrepancy. One explanation is that there are thousands of potential 
differential features in serum and the chance of two groups finding a common biomarker 
is low. However, it is unlikely to occur. Another more reasonable explanation is that 
those markers are subject to systemic bias. It is well known that the SELDI biomarkers 
are sensitive to experimental details or to serum storage condition even same condition 
was used. [139] 
Zhu et al. used peaks at m/z 7,772 and 3933 and Cui et al. selected peaks at m/z 
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2,055 and 3,166 for differentiating liver cirrhosis from healthy controls. Poon et al. 
reported 30 differential proteomic features and 7 of these together with serological 
markers were used to differentiate significant fibrosis. Compared our result with these 3 
studies, our results were only consistent with Poon et al. Two proteomic features (m/z 
9,498 and 9,714) were also found in our protein peaks list though these were not 
included in their diagnostic model. M/z 9,498 was believed to be m/z 9,452 in our study. 
This 9.5 kDa proteomic features showed negatively correlation with the Ishak scores in 
both studies. [119] 
The consistency with Poon et al. study was due to similar sample processing 
method and statistical design used. In our study and Poon et al., all samples were 
analyzed blindly without knowledge of the fibrosis stages. Pre-treatment samples were 
used for constructing diagnostic models. Spearman correlation test and SAM analysis 
were used to find differential proteomic features. SAM is a conservative multivariate 
bioinformatics test which allows the adjustment of median FDR and therefore a more 
reliable result could be achieved. Large proteomic data was usually encountered in 
proteomic profiling and more attention should be paid on multiple comparisons to avoid 
finding false differential markers by chance. Among 3 studies, only Poon et al. adopted 
the FDR approach and used correlation tests to search for differential peaks. Moreover, 
several SELDI studies also adopted this FDR concept in finding potential features from 
proteomic data. [140-142] Moreover, another criterion was set in our study. The 
differential proteomic features should be not only correlated with the degrees of liver 
fibrosis but also significantly higher or lower in patients with significant fibrosis. Mann-
whitney U test was used to find proteomic features which could differentiate between 
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with and without significant fibrosis. With these stringent criteria, the resulting 
differential proteomic features were therefore not likely identified by chance or selection 
bias. 
On the contrary, the discrepancy with these studies was due to several reasons. 
First, although all liver fibrosis/cirrhosis cases were HBV-associated, different controls 
samples were used. In Zhu et al. and Cui et al. studies, healthy patients were used as 
control while all recruited cases in Poon et al. were fibrosis cases from minimal fibrosis 
to cirrhosis which was the same as our study. It is obvious that different results can be 
obtained from different normal control. Second, different statistical designs can also 
give different results even using the same proteomic data. [143] Different statistical 
tools were used in model construction. Zhu et al. and Cui et al. used decision tree to 
construct the diagnostic models while Poon et al developed artificial neural network 
(ANN) models for prediction of liver fibrosis. Linear regression model was used in our 
study instead. This could explain that why the common differential peaks found in our 
study was not included in Poon et al. ANN model. 
In addition, previous studies of our team showed that case-control experiment 
design could lead to a discovery of a set of statistically valid differential proteomic 
features. However, only about 20% of them were genuinely associated with the diseases 
studied. [142][144] None of the previously published SELDI studies on discovering 
biomarkers for liver fibrosis had attempted to assess the biological relevance of the 
differential proteomic features. In the current study, in order to be considered as a 
potential diagnostic marker, the differential proteomic features needed to have 
association with at least 1 serological/biochemical biomarker reflecting liver function or 
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inflammation. This served as indirect evidence that the proteomic features had clinical 
meanings related to the liver fibrosis. Under these stringent criteria, only 4 proteomic 
features were found as potential markers in detecting liver fibrosis. 
In addition, the diagnostic model was validated with the post-treatment samples. 
To the best of our knowledge, none of the previously published SELDI studies provided 
this information. However, due to limited samples provided, most of pre- and post 
treatment samples were from the same patient group which might introduce sampling 
bias and confounding factors into our study. Sample heterogeneity between the pre- and 
post-treatment groups were studied and no difference was found in the mean fibrosis 
score and prevalence of the significant liver fibrosis between groups, showing there was 
no sample bias between discovery and validation groups. By comparing the biochemical 
and serological parameters between discovery and validation groups, result showed that 
significant differences were found in PT, ALB, ALP, AST, ALT and HBV DNA levels. 
This implied that the antiviral drugs effectively suppressed the viral load and some liver 
functions were recovered. 
Several preventative measures were done to avoid biased results caused by the 
nature of clinical samples used, sample storage conditions, experimental details, the 
mass spectrometric instrument, and/or bioinformatics analyses』143][145] All recruited 
patients, including non-liver fibrosis cases, were suffered from CHB infections. All 
serum samples were collected and processed in the same clinical center under the same 
laboratory settings. To ensure the quality of the serum samples, they were stored at -
80°C before analysis. 
For the diagnostic model construction, PT was the only serological/biochemical 
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markers included. PT is a blood test that measures how long it takes blood to clot. As 
all the clotting factors except factor VIII are produced by liver, the contents of these 
clotting factors will decrease if liver injury occurs. Therefore, measurement of PT is an 
indicator of liver function. People suffered from liver injury will have longer PT, 
showing that the liver lose its function to synthesize enough clotting factors for blood 
clotting. 
For pre-treatment group, the diagnostic model was useful in identifying cases 
with significant liver fibrosis in the CHB patients with AUROC = 0.726 (95% CI 0.605-
0.846，p < 0.005). Comparison between our diagnostic model and other non-invasive 
models in detection of liver fibrosis was performed. APRI, API and FibroTest (or 
Fibrosure in USA) were the non-invasive models developed for liver fibrosis and 
showed good accuracy in detecting liver fibrosis in some studies. Hongbo et al. reported 
that the AUROC of APRI in detection of liver fibrosis was 0.70 in a Chinese CHB 
cohort. [146] API, developed by Poynard et al mainly for CHC, [147] was evaluated by 
a Korean group in CHB cohort with AUROC = 0.751. [148] FibroTest (or FibroSure), 
constructed mainly for CHC-associated liver fibrosis, has been widely evaluated in the 
detection of liver fibrosis associated with different etiologies. A meta-analysis of 
FibroTest showed that the mean standardized AUROC was 0.84 (95% CI 0.82-0.87) and 
0.80 (95% CI 0.77-0.84) for patients with chronic hepatitis C and CHB, respectively. 
[149] As the sample size of this study was still small, it is difficult to conclude that the 
clinical performance of FibroTest was better than of our model in diagnosis of liver 
fibrosis in CHB patients. With available data, the diagnostic accuracy of APRI and API 
were calculated and compared with our diagnostic model. As two parameters included in 
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FibroTest equation such as GGT and a-2 macroglobulin were not available in our cohort, 
comparison between our diagnostic model and FibroTest could not performed. The 
AUROC of APRI and API were found to be 0.791 and 0.781 respectively which was 
consistent with recent studies. Our diagnostic model showed comparable result with 
these non-invasive models. 
However, from our result, APRI and API did not perform well in post-treatment 
samples with AUROC values of 0.633 (p = 0.130) and 0.676 (p = 0.045) respectively. It 
showed that these models were treatment-dependent. For APRI model, it performed well 
for pre-treatment samples but could not accurately classify significant fibrosis from 
minimal liver fibrosis patients. AST and PLT were involved in APRI model. As AST 
only reflected the liver injury, it did not represent the severe of liver fibrosis and the 
reduction of AST did not imply the reverse of fibrosis. In addition, AST was not 
significantly correlated with the degrees of liver fibrosis in our study. No significant 
difference was found between significant and minimal liver fibrosis group decreased its 
accuracy in APRI model. On the other hand, FibroTest was also found to be treatment-
independent. Poynard et al. reported that the AUROC for the diagnosis of advanced 
fibrosis was 0.76 both at baseline and after treatment. [150] Another longitudinal study 
indicated that the AUROC of FibroTest was 0.77 [151], showing stable performance 
upon antiviral therapy. It is worth noting the AUROC reported in these studies was 
similar to the value of our diagnostic model. Hence, we could conclude our diagnostic 
model and FibroTest both were useful in monitoring changes of liver fibrosis during 
antiviral treatment with similar accuracy. 
On the other hand, our diagnostic model consisted of PT as one of the parameters. 
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The accuracy of the model without PT was constructed and compared with our 
diagnostic model. It was found that the accuracy was dropped in model without PT 
parameter when classifying pre-treatment group. In addition, this model was unable to 
classify post-treatment group, indicating that PT was an important parameter in 
detecting liver fibrosis. 
For pre-treatment samples, the formed diagnostic model had a good accuracy in 
detecting liver fibrosis and cirrhosis. This allowed us to classify the liver fibrosis 
patients into 3 different risk categories with the use of high and low cut-offs, 3.0844 and 
1.3068. For those predictive score > 3.0844，they will be classified as high risk of liver 
fibrosis. Suspended patients with predictive score within 1.3068 and 3.0844 will be 
classified as medium risk. Those patients with predictive score < 1.3068 will be 
classified as low risk group. The positive predictive value for liver fibrosis in high risk 
group is 80%. This means 20 % of the cases with a positive blood test are false positive. 
Serious follow up, such as histological examination of liver biopsy, should be given to 
this group of high risk patients. For patients in medium risk group, they should be 
subjected to transient elastography for further examination. On the other hand, the 
negative predictive value in the low risk group is 96%, meaning that only 4 % of 
patients will be wrongly classified as low risk group. Low risk group will be excluded 
from both liver biopsy and antiviral treatment. For this group of patients, less aggressive 
follow-up, such as monthly blood test, can be provided. 
Though the model was treatment-independent, different cut-offs were set for pre-
and post-treatment. Another interesting finding was that same cut-offs were obtained for 
detecting fibrosis and cirrhosis. With the use of high and low cut-offs, 2.7303 and 
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0.3427, 3 different risk categories were made. For those predictive score > 2.7303, they 
will be classified as high risk of liver fibrosis. Suspended patients with predictive score 
within 0.3427 and 2.7303 will be classified as medium risk group. Those patients with 
predictive score < 0.3427 will be classified as low risk group. The negative predictive 
value in the low risk group is 92%, meaning that only 8 % of patients will be wrongly 
classified as low risk group. Low risk group will be excluded from both liver biopsy and 
antiviral treatment. For patients in medium risk group, they need to take liver biopsy for 
histological examination. 
For both treatment naive and post-treatment cases, it is worth nothing that similar 
high cut-off was obtained for both fibrosis and cirrhosis diagnosis. It may be due to the 
fact that our model was more applicable to detect liver cirrhosis than liver fibrosis. It 
might imply that our model was suitable in detecting liver cirrhosis instead of liver 
fibrosis. Another possible reason was due to the similar sample characteristics, the 
number of cases in fibrosis and cirrhosis groups were so similar that it was possible to 
get identical cut-offs with the same accuracy in these two groups. The model should be 
further investigated with larger sample group to confirm the reason for this phenomenon. 
However, the significant positive correlation between our predictive index and Ishak 
score strongly suggested that our model was useful for detecting both liver fibrosis and 
cirrhosis. 
Different cut-offs between pre- and post-treatment could be explained by the 
different values of PT and the peak intensities in pre- and post-treatment groups even at 
the same fibrosis stage. This was also due to small sample size issue and the cut-off 
values carried certain degrees of error, making different cut-off values in two groups. On 
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the contrary, as the AUROC values were similar, the diagnostic performance of the 
model was not greatly affected. Further studies with larger sample size are needed 
before we could decide whether different cut-offs should be set for pre- and post-
treatment groups. 
I l l 
2.5 Conclusion 
Using the in-house magnetic bead-based proteomic profiling assays, 4 potential 
proteomic markers were found for the diagnosis of liver fibrosis in CHB patients. A 
diagnostic model composed of 2 proteomic markers (m/z values of 9,165 and 12,443) 
and PT was constructed. Independent validation showed the diagnostic performance of 
this model was comparable to those non-invasive diagnostic models previously 
published. However, it appeared that our model was more superior because our model 
maintained similar diagnostic performance for the serum samples collected after 
antiviral treatment. 
112 
Section 3 Identification of proteomic features to form diagnostic 
fingerprint for the detection of liver fibrosis in patients with chronic 
hepatitis B infection 
3.1 Introduction 
As mentioned, SELDI has become a useful tool in proteomic profiling for different 
diseases in biomarker discovery. However, only knowing the mass values of the 
differential protein peaks limits its usefulness and significance in clinical field. Wu et al. 
discovered 45 differential protein peaks between HBV-related hepatocelluar carcinoma 
(HCC) and liver cirrhosis groups. [152] Among them, two protein features (m/z 9,297 
and 29,941) and AFP were selected to form a diagnostic model with 79.3% sensitivity 
and 90.0% specificity. As the protein identities were unknown, the validity and 
significance of protein biomarkers could not be evaluated. Furthermore, without 
differential peak identities, it was impossible to study why such abnormalities would 
occur and how the disease enhances such effects. This was well illustrated by Liu et al. 
[153] Factor analysis was performed from SELDI MS data to characterize serum low-
molecular weight proteins/peptides in liver injury. A group of proteins/peptides was all 
down-regulated in hepatitis serum samples and factor analysis showed that they were 
highly correlated and influenced by the same factor. However, since the protein 
identities of these protein group as well as their chemical properties were unknown, it 
was not possible to draw definite conclusion regarding the nature of the peaks and 
factors. 
Also, protein identity could provide evidence that the differential protein peaks 
were not artifacts which were common in biomarker discovery studies. In addition, 
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doubly or triply charged protein signals were usually occurred in SELDI-TOFMS. 
Sometimes the same protein with different charges may be selected in the same 
diagnostic model which could affect the diagnostic accuracy. [154] On the other hand, 
wrong classification of a protein as a multiple charged species can lead to a loss of 
useful information. The only solution was protein identification of the interested peaks. 
Kanmura et al. found a numbers of peaks that might represent doubly charged peaks. 
They suspected that the differential peaks at 4,067 m/z might be the doubly charged 
form of the 8,138 m/z peak. Surprisingly, after protein identification, they concluded 
that the peak at 4,067 m/z did not appear to be the doubly charged of 8,138 m/z peak. 
This demonstrated that protein identification was indispensable for biomarker discovery 
before concrete conclusion could be made. 
The major limitation of SELDI technology was that the retained proteins on the 
proteinchip could not be recovered for protein identification. Other purification 
techniques were needed to enrich the corresponding proteins. This made the whole 
procedures complicated and tedious. Several approaches had been reported to enrich the 
interested proteins. Zinkin et al enriched the interested SELDI peak by using a spin 
column containing Q Ceramic HyperD F beads. The column was washed thrice with 
50mmol/L Tris (pH9) and incubated with diluted serum (40^iL serum + 500jxL 
50mmol/L Tris (pH9) for 90 minutes. The column was then washed with 150|iiL of 
50mmol/L Tris (pH9) twice and the flow through pooled and dried in a Speedvac 
centrifuge for 1-D SDS PAGE. Wu et al proposed that the biomarkers could be purified 
by using affinity capture, anion exchange, size exclusion and reversed-phase 
chromatography depending on their individual biochemical properties. [132] 5 mL of 
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serum was first subjected to blue sepharose to deplete albumin, the remaining proteins 
were then separated by CI8 reverse-phase chromatography. The purified biomarkers 
were further digested and subjected to ESI-MS/MS for sequence identification. 
Alternately, the fractions obtained from liquid chromatography could be further 
separated by SDS PAGE. The interested band was then excised, digested and identified 
by MALDI-TOF-MSMS. Another approach was ACN precipitation reported by He et al. 
[155] Pure ACN was added to 200(iL of serum to remove high molecular weight 
proteins. The supernant was then concentrated for 2D-PAGE analysis. All methods 
required large amount of serum which might not be affordable by many research groups 
as patient samples were limited. 
Western blotting and immundepletion/immunoprecipitation was usually followed 
to confirm the protein identity of the interested peak. [156] Furthermore, immunoassays 
were also done to confirm the identities of the biomarkers and evaluate the feasibility of 
using these biomarkers for clinical use. [135] 
In this section, we aimed to identify the protein identities of the protein features 
selected in the diagnostic model by using the developed methodology mentioned in 
section 1. The validity of the protein identity to the targeted peak was then confirmed by 
immunodepletion. The concentrations of the biomarkers were then further quantified by 
immunoassay. 
3.2 Materials and methods 
3.2.1 Non-reducing 2-D gel electrophoresis 
Proteins eluted from the magnetic beads was dried at 45 °C using speedvac 
concentrator (Enppendorf) and reconstituted with 185^L of rehydration buffer (8M Urea, 
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2% CHAPS, 0.2% Biolyte 3-10 ampholyte, 0.001% bromophenol blue, ImM EDTA). 
An immobilized pH gradient (IPG) strip (11cm 3-10NL, Bio-Rad Laboratories) was 
rehydrated with the sample overnight. For the first dimension IEF separation, the 
running condition was as follows: 100V for lOmin, 250V for 65min, 500V for 25min, 
1000V for 40min, and finally 8000V for 140min. Second dimension SDS-PAGE was 
performed on 4-12% Bris-Tris polyacrylamide gels (Bio-Rad Laboratories) and the 
proteins were separated at 200 V for 40min in ice bath. The 2D gel was then stained 
with silver nitrate using Amersham PlusOne silver staining kit (GE Healthcare) with 
some modifications to reduce the loss of proteins with M W < 10 kDa. The gel was fixed 
in 40% methanol/10% acetic acid for 30 min and then sensitized by thiosulfate solution 
with 25% w/v Glutardialdehyde. Washed with 30% ethanol for 15 min, the gel was 
immersed with silver solution in 30% ethanol and 37% w/v formaldehyde for 1 hr. The 
gel was washed with Milli-Q water for lmin for 3 times and then developed in sodium 
carbonate solution with 37%w/v formaldehye. The development was stopped by EDTA 
solution and the gel was rinsed with Milli-Q water for 3 times before performing image 
analysis with GS-800 calibrated densitometer (Bio-Rad Laboratories). 
3.2.2 Protein identification of eluted proteins 
Protein spots were excised from silver stained gels. The gel pieces were 
destained, reduced with 1.75% DTT，alkylated with 350 mM IAA, and digested with 
modified porcine trypsin overnight (Sequencing grade modified typsin from Promega, 
Madison, WI). The tryptic digest was harvested and cleaned up with C I8 ZipTips 
(Millipore). The cleaned tryptic peptides were subjected to MALDI-TOF/TOF MS 
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(Ultraflex-III, Bruker Daltonics) with a-cyano 4-hydroxy cinnamic acid as matrix. The 
MS and MS/MS spectra were then processed with Data Explorer software (Flex analysis 
3.0). The spectra were subjected to Gaussian smoothing with a filter width of 5 points, 
and the baselines were corrected with default settings. Peaks were detected based on a 
S/N > 15. The MS spectrum data were searched via the online Mascot search engine to 
obtain the protein identity by undertaking the peptide mass fingerprinting (PMF) 
approach. Tandem MS data were subjected to MS/MS ion search via the Mascot search 
engine to obtain the protein sequence of a particular peptide. For the search parameters, 
the 1 missed cleavage in trypsin digestion was allowed; partial oxidation of methionine, 
phosphorylation of serine/threonine/tyrosine, and iodoacetamide modification of 
cysteine residues were selected. The error tolerance values of the parent peptides and the 
MS/MS ion masses were 200ppm and 0.5 Da, respectively. A protein identification 
result was considered valid when both PMF and MS/MS ion search identified the same 
protein as the statistically significant hit from the NCBInr database, and/or when 
MS/MS ion search identified at least tryptic peptides with sequences from the same 
protein as the statistically significant hits. 
3.2.3 Immunodepletion of apolipoprotein C-III 
Protein G Agarose bead (Pierce®) was used to capture polyclonal goat anti-human 
apolipoprotein C-III antibody (Abeam) to deplete apolipoprotein C-III in serum. 3 
conditions were set: Sepharose 4B with antibody, Protein G Agarose without and with 
anti-apolipoprotein antibody. The first two conditions were served as negative controls. 
Briefly, beads were pre-equilibrated with PBS buffer for 3 times. Then, 40jxL of anti-
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apolipoprotein antibody or PBS buffer (negative control) was added to the beads and 
incubated at 4 °C overnight. The supernant was then removed, and the beads were 
washed with PBS buffer for 3 times. 2 ^L of serum samples diluted 100-fold in PBS was 
added to the washed beads and incubated at 4°C overnight. The supernatant was finally 
collected for serum proteomic profiling using the developed method, as described in the 
previous section. Figure 21 showed the experimental flow of the immundepletion assay. 
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Positive control: Negative control 2: Negative control 1: 
Protein G Agarose (Pierce®) Sepharose 4B (Amersham) Protein G Agarose (Pierce®) 
^ ^ ！-
Wash gel with PBS 
1 4 • 
Incubate with anti-app C-III at 4'C overnight Incubate with PBS at 4'C overnight 
• fl • . 
Wash gel with PBS 
Incubate with serum sample at 4'C overnight 
( fl • 
Collect supernatant for magnetic beads protein profiling 
Figure 21 Experimental flow of the immunodepletion assay 
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3.2.4 Measurement of serum levels of apolipoproteins 
Human apolipoprotein LINCOplex kit (Millipore) was used to measure the amount 
of apolipoproteins (apoA-I, apoA-II, apo B, apoC-II，apoC-III and apoE) in patient 
serum. 2jaL of whole serum was diluted in 50,000 fold with assay buffer (10 mM PBS 
with 0.08% Sodium Azide and 1% BSA, pH 7.4). The whole procedure was followed by 
manufacturer's protocol. Briefly describe 10|a.L of the diluted samples or calibration 
standards were added to each well and mixed with antibody-immobilized beads for lhr 
incubation. After washing with washing buffer (10 mM PBS with 0.08% Sodium Azide, 
and 0.05% Tween 20, pH 7.4)，detection antibody was added to each well and incubated 
for 30min. With 3 washing steps, Streptavidin-Phycoerythrin was added to each well 
and incubated for another 30min. Shield fluid was finally added to each well. The 
concentration of the apolipoproteins was then measured by Bio-Plex 200 system (Bio-
Rad Labs). 
3.2.5 Statistical Analysis 
Spearman rank correlation analysis was performed to investigate the correlation 
between concentrations of apolipoproteins and the degree of liver fibrosis in serum level. 
The correlation between the protein peak intensity of 9,153 m/z and the concentration of 
apolipoprotein C-III measured from LINCOplex kit was studied. 
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3.3 Results 
3.3.1 Protein identification of the protein marker in the diagnostic model 
It was obvious that the overall protein quantity of the low peak intensity gel 
(samples with minimal 9.2kDa and 12.4 kDa peak intensity) was less than that of high 
peak intensity gel (samples with intense 9.2kDa and 12.4 kDa peak intensity)while the 
gel pattern was the same (Figure 22). Gel pattern was similar between the two gels, 
indicating the gels were undergone similar condition and background. By studying the 
intensity contrast of these two gels with mass estimation from the protein gel marker, 
several spots were excised and protein identification work was done. The marked area 
on the gel photos were the potential protein spots corresponding to 9.2kDa and 12.4 kDa 
protein peaks. The 9.2 kDa protein selected in the predictive model was found to be 
apolipoprotein C-III (apo C-III). 2 peptides were matched in Mascot MS/MS database 
with a score of 166 (expected value = 5.13 e-13). The two peptides were m/z 1,716 and 
m/z 2,016 and the corresponding peptide sequences were K. DALSSVQEQVAQQAR. G 
and K. TAKDALSSVQESQVAQQAR. The resulting spectra and the corresponding 
database search result were shown in Figures 22-24. The protein identity of 12.4 kDa 
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Figure 23 A) The peptide mass fingerprinting spectrum of 9.2kDa. B) Mass list of PMF spectrum of 
9.2kDa. 
123 
Intens.J ~ —~~:—— ~ 
【a.u..】:： (fj_Z16_91_g 
x1。4. ； ： 乂 




0 . 5 -
1 2 9 9 7 Q 9 
L 1 4 S 3 8 3 8 2 Q 1 6 8 9 9 2 3 8 3 5 2 3 2 7 1 6 . 2 6 3 
1 0 O O 1 5 0 0 2 0 0 0 2 5 0 0 m / z 
""'[air] .2^.^,..01^ 
(f^Oia 89S ) I 
K.TAKDALSSVQESQVAQQAR.G 
3 0 0 
200-
1 0 ° ： I I 
1 &30 ree 
""".....190C> ' .' if boo “ “ 2100"'.一-t ‘ “ . . . . . . .— -
Resu l t s List 
I, APCC3_HUMM： M*ss : 1C84 6 S c « r # : 166 E * p « c t : 5. le-13 Qu«cs.«s m a t c h e d ; 2 
Apolipoprotein c-lll sapiens gn=a?C€3 ?E=1 sv=: 
O b s e r v e d Mr (expt> Mr ( c a l c ) ppn S t a r t E n d M i a 3 I o n s P e p t i d e 
1 7 1 6 . 1 1 1 1 . 3 7 3 1 1715.8438 2S.8 4 5 - cC 3 12 3 K.. CALSSV^LSQ'.'AQiAR. G 
2016,8904 2015.B831 2'16.023^ -€9.6'： 42 - c-： ： 23 K.TAKVhlSSVQES'SVAQQhR.<：• 
Figure 24 Zoomed spectra showing the two matched peptides o f apo C-III 
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3.3.2 Immunodepletion of apolipoprotein C-III 
To further confirm the m/z 9,165 proteomic feature was apo C-III, 
immunodepletion assay specific to apo C-III was performed. Depletion of apo C-III was 
only observed when both protein G agarose and anti-apo C-III antibody were present 
(Figure 25). 3 peaks (9,165, 9,452 and 9,735 m/z) were depleted while other peaks were 
not affected. Except these 3 peaks, similar profile patterns and intensities were observed 
in both the experimental condition and the negative controls. The peak intensities of 
9,165, 9,452 and 9,735 m/z in the negative controls were comparable to the profiles 
without immunodepletion, showing that the sample loss was negligible during sample 
manipulation. When protein G-beads were replaced with Sepharose 4B beads, 3 peaks 
were not depleted. This was consistent to the fact that the anti-apolipoprotein could not 
bind to the Sepharose 4B bead surfaces and therefore no depletion could take place in 
this condition. As a result, this immunodepletion experiment confirmed that m/z 9,165 
proteomic feature was a variant of apo C-III. Our result also showed that proteomic 
features at m/z 9,452 and m/z 9,735 were other two variants of apo C-III. 
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Figure 25 The proteomic profiles of a representative serum sample before and after immunodepletion of 
apo C-III. 
A: Not subjected to immunodepletion; B: Only Protein G beads was included during immunodepletion; C: 
Sepharose 4B beads and anti-apo C-III antibody were included; D: Protein G beads and anti-apo C-III 
antibody were included. 
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3.3.3 Serum levels of Apolipoproteins and Their Associations with Liver Fibrosis 
Serum concentrations of six apolipoproteins, including apo C-III, were measured, 
and correlation analysis between their serum concentrations and Ishak scores were 
carried out. Two apolipoproteins, apo A-II (r = -0.156，p = 0.016) and apo C-III (r = 
0.153, p = 0.019)，were negatively correlated with the degree of liver fibrosis. Other 
apolipoproteins did not show statistical significance with the progression of liver fibrosis. 
The correlations between six apolipoproteins and the Ishak scores were summarized in 
Table 13. 
As expected, the intensities of the 2 protein peaks corresponding to apo C-III 
variants, i.e. peaks at m/z 9,165 and 9,452，were positively correlated with the apo C-III 
concentration obtained by immunoassay with correlation coefficient of 0.257 (p = 0.015) 
and 0.223 (p = 0.036) respectively. For m/z 9,735 peak, it could be considered as 
marginally significant. In addition, the sum of these 3 peak intensities also showed 
positive correlation with the apo C-III concentration (r = 0.245, p = 0.020). Table 14 
showed the correlations between different peaks and the apo C-III concentration. 
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Table 13 Correlation between apolipoproteins and Ishak scores. (*p <0.05) 
Apolipoprotein Correlation coefficient p-value 
"Apo A-I -0.071 ~0278~ 
"Apo A-II ^ 1 5 6 0.016*~ 
"ApoB ~a042 "0.515 
"Apo C-II :0.120 0.064 
"Apo C-III 1 . 1 5 3 0.019* 
"Xpo E <0.0005 0.992 
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Table 14 Correlation between protein peaks intensities and apo C-III concentration (*p <0.05) 
Proteomic feature Correlation p-value 
coefficient 
"9,165 m/z 一 0.257 ~0.015* 
"9,452 m/z ~ 0.223 ~OQ36* 
"9,735 m/z — 0.204 ~QjQ55 
Percentage of 9,165 m/z p e a k 0 . 0 4 9 0.624 
intensity 
Percentage of 9,452 m/z peak -0.076 0.445 
intensity 
Percentage of 9，735 m/z peak 0.073 0.462 
intensity 
"Sum of 3 peaks 0.245 0.020* 
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3.4 Discussion 
2-D PAGE followed by in-gel digestion was a common approach used for protein 
identification. 1-D SDS PAGE or 2-D PAGE could be used, depending on the 
complexity of the protein fraction. 2-D PAGE was used in this study was mainly 
because the eluted proteins consisted of many proteins with similar molecular weights. 
Proteins with similar molecular weights would appear as one single band in 1-D SDS 
PAGE, and were not suitable for protein identification. 5 samples with most intense / 
minimal peak intensities of 9.2 kDa and 12.4 kDa were pooled separately to find the gel 
spots corresponding to the interested peaks. By comparing the intensity contrast of the 
two gels with the help of protein marker for mass estimation, potential gel spots were 
selected, excised and digested for sequence identification. Apo C-III was successfully 
identified for m/z 9,165 peak in the diagnostic model. Unfortunately, protein identity of 
m/z 12,443 peak was still unknown. The failure could be explained by the following 
reason. It might be because the peptide sequence was not available in the database or the 
protein spots were mixed with other proteins so the targeted protein was masked by 
other proteins. 
Immunodepletion of apo C-III was carried out to confirm the identity of m/z 9,165 
peak. It was confirmed by depleting the 9,165 m/z peak in an experimental condition. 
The anti-apo C-III specifically bind to the Protein G beads for depleting apo C-III in 
serum but not for Sepharose CL 4B beads. Polyclonal goat apo C-III antibody with IgG 
isotype was used for immunodepletion. Protein G is a bacterial cell wall protein 
expressed in group G Streptococci. It binds to most mammalian immunoglobulins 
primarily through their Fc regions. Native Protein G contains two immunoglobulin 
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binding sites, as well as albumin and cell surface binding sites. However, since albumin 
appears as the major contaminant in serum, a recombinant form of protein G which 
albumin and cell surface binding sites are eliminated is made to reduce nonspecific 
binding. Sepharose CL 4B beads do not have immunoglobulin binding sites for anti-apo 
C-III and therefore depletion cannot occur in Sepharose CL 4B condition. After 
immunodepletion, other protein peaks remained unaffected in terms of peak shape and 
intensity, showing that depletion was so specific to the particular proteins and magnetic 
beads-based proteomic profiling was not affected by immuodepletion. 
Together with 9,165 m/z, two other neighboring peaks (9,452 and 9,735 m/z) 
were also depleted by apo C-III antibody, indicating that there were 2 other isoforms of 
apo C-III detected in the magnetic beads proteomic profile. According to the literatures, 
apo C-III consists of 79 amino acid residues and exists in three isoforms depending on 
the number of post-translational sialyl groups (0 to 2) terminating the oligosaccharidic 
portions of the protein. The sugar moiety of apo C-III consists of 1 galactose, 1 N-
acetyl-galactosammine and 0, 1 or 2 sialic acids molecules. [157] These three isoforms, 
apo C-IIIo, apo C-IIIi and apo C-III2 contribute 10，55 and 35 % of total apo C-III 





























































































































































































































































































































Sialic acid is a family of N- and 0-substituted derivatives of neuraminic acid 
which is an amino sugar. [158] Over 40 naturally occurring derivatives have been 
identified and the most common sialic acids found on human plasma proteins and 
glycolipid is 5-N-acetylneuraminic acid. The functions of sialic acids in biological 
system include conformation stabilization, protease resistance, charge, enhancement of 
water binding capacity, cellular recognition, protein targeting and developmental 
regulation. The sialylation of apolipoprotein is still not completely understood; however, 
it is known that the sialic acid content of individual apolipoi)roteins w川 vary in 
response to physiological conditions. Disease states may selectively alter any 
biosynthesis stage and passed into plasma, generating an altered glyco-isoform 
distribution. [159] Glycomic structures and distributions may therefore provide insight 
into disease mechanisms that impact on cellular events leading to protein export. 
Apolipoprotein sialylation is an intracellular process driven by Golgi-membrane-bound 
enzymes, sialyltransferases. The glycol-isoform ratio change has been studied for 
various diseases. Excess sialylation of apo C-III, apo C-III2, was found in 
hypertriglyceridemic subjects. This may be due to its higher affinity for VLDL than apo 
C-IIIo and apo C-III 1. Also, apo C-III2 is a poorer inhibitor of VLDL binding to the 
purported lipolysis stimulated receptor than apo C-IIIQ and apo C-IIIi. Harvey et al 
demonstrated that the apo C-IIIi/ apo C-III2 ratio changed on bariatric surgery, chronic 
or severe liver disease. [159] A decrease in apo C-IIIi/ apo C-IIb was found after 
bariatric surgery while it was increased by liver disease. However, other studies showed 
that no significant difference was found in the distribution of these three apo C-III 
isoforms in a CHC study. [160] Mauger et al also reported that no correlation was 
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observed between the relative proportion of each isoform and anthropometric variables 
and suggested that the degree of sialylation of apo C-III might not be related to neither 
plasma lipid levels nor obesity indices. [161] Our study followed the latter results. In our 
study, all three apo C-III isoforms were down-regulated with the degree of liver fibrosis. 
Furthermore, positive significant correlations were found between the three isoforms, 
further validating the coherent of the correlation direction trend. From our result, there 
was no implication that the degree of sialylation was related to liver fibrosis as the 
relative proportion of apo C-III was not significantly correlated with liver fibrosis. Our 
results might be account for our purposed mechanism rather than sialylation of apo C-III. 
In addition, our result was consistent with our previous pilot study. [119] Two protein 
peaks, 9,498 and 9,714 m/z were negatively correlated with liver fibrosis. It was 
believed that these 2 peaks were sialylated forms of apo C-III. Also, Molina et al. 
reported that apo C-III was a candidate biomarker in plasma associated with the 
resolution of HCV infection. [160] These two studies further supported our result that 
apo C-III was associated with liver function. It also implied that apo C-III was not only 
valid in CHB but also in CHC cases. Further studies were needed to examine the clinical 
performance of apo C-III in detecting liver fibrosis caused by different etiologies. 
Apo C-III is the most abundant C-apolipoprotein in human and is found on the 
surface of very low density lipoprotein, low density lipoproteins, chylomicrons and high 
density lipoproteins (HDL). [162][163] Apo C-III is mainly synthesized in liver and 
intestine. It is a well known inhibitor of lipoprotein lipase and hence delays lipoprotein 
triglyceride lipolysis. Overexpression of apo C-III leads to the increase in plasma 
triglyceride levels. Apo C-III is thought to interfere with the binding of apo C-II to 
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lipoprotein lipase and to prevent binding of apo B particles to LDL receptors. Elevated 
apo C-III level is usually found in patients with metabolic syndrome and has also been 
associated with insulin resistance. Also, it has been implicated in coronary artery disease. 
It was shown that lifelong deficiency of apo C-III had a cardioprotective effect. [164] 
On the contrary, in our study, apo C-III was down-regulated in CHB patients with 
liver fibrosis which was an opposite situation to most lipid and cardiovascular studies. 
The cause of this down-regulation might be associated with the dysregulation of TGF-pl 
in fibrogenesis. TGF-pl, a well studied cytokine, is believed to play a key role in 
fibrogenesis. TGF-pi carries out multiple biological functions including development, 
cell growth, differentiation, ceil adhesion, migration and contribution to the regulation 
of the production, degradation and accumulation of ECM proteins. High levels of TGF-
(31 are often found in liver fibrosis and it has been considered as a mediator of liver 
fibrosis. It is well known that liver fibrosis occurs under the activation of quiescent 
HSCs that will further enhance the growth of myofibroblasts to disrupt the liver 
architecture. Researches found that this consequence was associated with the 
overexpression and activation of TGF-pl, implying that TGF-pl may be one of the first 
signals to activated quiescent HSCs. TGF-pl enhances ECM synthesis as well as 
inhibits ECM degradation by suppressing expression of matrix-degrading enzymes and 
promoting expression of matrix metalloproteinase inhibitors (MMP). [165] 
Hepatocyte nuclear factor -4a (HNF-4a), an apo C-III target gene, was inhibited by 
TGF-pl. [166] It was showed that TGF-pi affected both HNF-4a mRNA and protein 
levels by decreasing the DNA-binding capacity of HNF-4a and inducing degradation of 
HNF-4a in the proteasome in HepG2 cells, respectively. HNF-4a is abundant in liver, 
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intestine, pancreas and kidney. It is a highly conserved member of the nuclear receptor 
superfamily that was initially identified as a transcriptional factor required for liver-
specific gene expression. [167] It generally acts as a positive transcriptional regulator of 
many hepatocyte genes. HNF-4 was shown to be an important candidate for liver 
development; expression levels of large number of genes whose products were essential 
for mature liver function were disrupted in HNF-4 null livers. [168] In addition, Lucas et 
al postulated that the loss of hepatic specific functions during the progression of liver 
fibrosis could be explained by the inhibition of HNF-4a by TGF-|31 and nitric oxide 
(NO). [166] Moreover, many studies reported that apo C-III gene was transcriptionsally 
dependent on HNF-4a in the liver, by interacting at least two sites of the apo C-III 
promoter. [169-171] Therefore, the reduction of apo C-III in liver fibrosis patients might 
be due to the inhibition of HNF-4a. 
As apolipoproteins are mainly synthesized in liver, their contents in plasma may 
reflect liver function. Also, the association of apolipoproteins A1/C3/A4/A5 gene cluster 
that modulates plasma triglycerides reveals the inter-correlation of different 
apolipoproteins which may be also related to liver fibrosis. [172] Therefore, after 
identifying apo C-III as one of the diagnostic markers in detecting liver fibrosis, 
immunoassay in quantifying six apolipoproteins was carried out to study the correlation 
between other apolipoproteins and liver fibrosis. 
Apart from apo C-IIl, other apolipoproteins such as apo A-I, apo B and apo E have 
been studied and found to have clinical values in liver diseases. Apo A-I was correlated 
with patients with chronic liver disease such as primary biliary cirrhosis [173] and liver 
fibrosis. [48] [174] It has been included in several non-invasive models in detecting liver 
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fibrosis like FibroTest [175] and PGAA index. [176] Apo B levels were significantly 
lower in patients with CHC. It was negatively correlated with steatosis and HCV viral 
load and became an indictor to confirm the interaction between hepatitis C infection and 
p - lipoprotein metabolism. [177] For apo E, Ferre et al reported that 
hypercholesterolemic ApoE-/- mice were more susceptible to develop severe liver injury. 
[178] Also, the mRNA level of apo E was found to be down-regulated to the liver injury 
in mice model. [179] 
However, among six apolipoproteins (apo A-1, A-II, B, C-II, C-III and E), only apo 
A-II and C-III were negatively correlated with the degree of liver fibrosis in our study. 
This finding was consistent with recent study. [180] D.Q. Shih et al found that patients 
with HNF-4a mutation had a significant reduction in apo A-II and apo C-III but not in 
apo A-I and B though they were all HNF-4a target gene and mainly expressed in the 
liver. By further genotypic and phenotypic comparison, they confirmed that these 
reductions were due to HNF-4a haploinsufficiency rather than factors from family 
aggregation or diabetes. It was known that both apo A-II and C-III genes contained an 
HNF-4a binding site and therefore this reduction could be explained by the decreased 
binding capacity ofHNF-4a caused by TGF-pl in our proposed mechanism. [181] 
The down-regulated correlation between apo C-III and liver fibrosis in the 
immunoassay further validated the clinical significance of apo C-III found in our 
diagnostic model. By investigating the correlation between the protein peak intensities 
of apo C-III (9,165, 9,452 and 9,735 m/z) and their corresponding apo C-III 
concentration in serum, significant positive correlation result gained the validity of these 
three peaks as apo C-III. However, the correlation was low and the sum of the 3 
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isoforms peak intensities did not show great improvement in the correlation between the 
apo C-III concentration. Though 3 major apo C-III isoforms were found in proteomic 
profile, there was still a number of variants reported in other studies [157][182][183] 
cannot be detected in our system. This could explain the low correlation coefficient 
between peak intensities of apo C-III variants and apo C-III concentration measured by 
immunoassay. 
Though apo A-I was currently included in two common non-invasive models, there 
were still some studies reported that it was not correlated with liver fibrosis which was 
accordant with our result. Lebensztejn DM et al. found that apo A-I was not 
significantly different in patients with CHB infection compared with the controls. [184] 
Lu et al further pointed out that there was an ethnic difference in the normal range of 
apo A-I. The concentration of apo A-I in controls was abnormally high compared with 
those in foreign countries for a CHB study in China, making it inapplicable to PGA and 
PGAA models. [185] Another CHB study by Selimoglu MA et al. also showed the same 
result. [186] This discrepancy may be account for the differences of ethnicity and 
etiology of the patients as FibroTest and PGAA index were mainly used for hepatitis C 
infection and alcoholic liver diseases respectively. Nevertheless, a study showed that 
apo A-I was a biomarker for hepatitis B virus infected liver inflammation. [187] 
Apolipoprotein A-I presented heterogeneous change in expression level with different 
isoforms specific to HBV infection. Further study on apo A-I in CHB studies against 
other liver diseases is needed to sort out this discrepancy. No correlation between apo B 
and liver fibrosis could be explained by the difference in etiology. Apo B was found to 
be associated with HCV in plasma. A CHC study illustrated that higher apo B-
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associated cholesterol was positively correlated with CHC patients after receiving anti-
viral treatment. Sherudan et al. proposed this might due to competition between apo B-
containing lipoproteins and infectious low-density HCV lipo-viral particles for 
hepatocytes entry via shared lipoprotein receptors. [188] On the other hand, although 
several studies demonstrated that decreased expression of apo C-II was found in biliary 
atresia-associated liver cirrhosis patients and suggested it was a novel substrate for 
matrix metalloproteinases [189] [190], no correlation between apo C-II and liver fibrosis 
was found in our study. Despite apo C-II, like apo C-IlI, belongs to the C class of 
apolipoproteins, no recent non-invasive model or study reported apo C-II was a 
biomarker in detection of liver fibrosis. Further investigation is needed to elucidate its 
significance in clinical use. Apo E has been found to be correlated with liver function in 
mice model and related to lipid metabolism. However, its importance and usefulness to 
liver fibrosis in human remains unclear and need further investigation. 
3.5 Conclusion 
The m/z 9,165 proteomic feature, which was one of protein markers selected in 
the diagnostic model, was identified to be apo C-III by mass spectrometry. Subsequently, 
it was confirmed by immunodepletion. Two peaks (m/z 9,452 and 9,735) were also 
confirmed to be isoforms of apo C-III. Concentration of apo C-III obtained by 
immunoassay was negatively correlated with Ishak score. The positive correlation 
between the depleted protein peaks and apo C-III concentration was found. Another 
apolipoprotein, apo A-Il, was also negatively correlated with the progression of liver 
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fibrosis. Magnetic bead-based proteomic profiling is able to find biomarkers in the 
detection of liver fibrosis in patients with CHB infection. 
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General discussion 
After the completion of human genome project (HUGO) in 2003 [191], proteomics 
has become another important research area in biomarker discovery. Proteomics, which 
is defined as the study of proteome, has been widely applied to studies of the protein 
expression levels, structures and protein-protein interactions. [192] With advanced 
technology, complex protein mixtures could be well separated and analyzed by MS 
technology to study the protein expression, finding biomarkers for various diseases. 
Protein expression profiling has been considered as a new strategy for biomarker 
discovery and the disease-associated/specific "fingerprinting" or "proteomic pattern" is 
used as a biomarker. [193] 
In our study, using a magnetic beads-based platform we successfully developed an 
in-house proteomic profiling method that allows both quantitative analysis and micro-
scale purification in parallel. Similar to the SELDI technology, a subset of proteins with 
definite chemical properties were retained and screened for disease-associated proteins. 
Disease-associated proteins were found by comparing the protein contents between 
disease and control groups which was regarded as comparative proteomics. Large 
sample size was needed so that good statistical power could be achieved for searching 
biomarkers. Therefore, high-throughput technology is indispensable for a large scale 
study. Our developed method, magnetic-beads platform allows analyzing 96 samples in 
one batch which greatly reduces the experimental time and enhances reproducibility. 
The other concern is the specificity of the biomarkers. Serum amyloid A (SAA), an 
acute phase protein, was found to be a biomarker for various disease such as renal 
cancer [89], nasopharyngeal cancer [194], hepatocelluar carcinoma. [155] The non-
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specificity of SAA made it not suitable for clinical use when is used alone as a 
biomarker. Furthermore, it seemed that SAA responded to inflammation rather than 
carcinogenesis. [195] In addition, high abundance proteins in plasma/serum are the 
major problems in proteomic profiling. Competition occurs during sample binding and 
those large and high abundance proteins usually mask low abundance proteins. 
Transferrin, ranked as of the most abundance proteins [83], was found as biomarker 
for certain diseases like breast [196] and ovarian cancer. [197] The usefulness of this 
kind of high abundance protein is usually limited. It is believed that disease-associated 
markers released by a very small tumor/defected area and their microenvironment 
should be at very low level and probably in )xg/L level like prostate specific antigen 
(PSA). [139] [143] Diamandis pointed out that SELDI technology could only detect 
proteins in mg/L level which is 1000-fold higher than the concentration of known tumor 
markers in the circulation. For apo C-III found in our study, the concentration was 60-
180 mg/L in healthy person. Though it was not as high abundance as apolipoprotein A-I 
and transferrin (1,000-3,600 mg/L), it was far higher abundance than those known 
biomarkers. [83] 
In the future, it is important to develop novel high-throughput technologies to 
profile the low abundance proteins in the serum/plasma samples for patients with 
different degrees of liver fibrosis. Penetration into the deep proteome therefore becomes 
the main challenge in discovering low abundance biomarkers. It is well known that high 
abundance proteins always mask the detection of low abundance proteins, a potential 
source of biomarkers under assumption that only a subtle difference may occur and is 
reflected to the bloodstream at the early stage of the disease. The high dynamic range of 
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proteins can be compressed by the use of large-bead-based library of combinational 
peptide ligands (Equalizer beads or ProteoMiner) to enrich the low abundance proteins. 
Sihlbom et al. investigated the feasibility of the combined use of the Equalizer beads 
with SELDI or 2-D DIGE to improve the protein profiling compared with the depleted 
method. [198] They showed that better resolving efficiency and reproducibility were 
achieved using beads technology compared with multiple affinity depletion columns. 
High abundance protein such as albumin was greatly reduced and more gel spots could 
be resolved from the sample depleted with Equalizer beads. 
Traditionally, the high abundance proteins were depleted by immunodepletion 
based on dye-ligands or specific antibodies. [199] However, it is subject to some 
limitations. It is a low throughput and time consuming process as the abundance proteins 
are depleted accordingly. Certain amount of low abundance proteins are co-depleted out 
with the removal proteins and information on these low abundance proteins may be lost. 
Furthermore, the large dynamic range is only reduced by removing the high abundance 
proteins; there is no concentration step on low abundance proteins which still limits the 
chance of detecting the low species. Indeed, this depletion step will further dilute the 
sample as larger elution volume is obtained compared with the original sample. [200] A 
rather new method, Equalizer bead, has been introduced to compress the high abundance 
proteins and enrich the low species simultaneously with no further dilution on the 
elution sample. Its principle is based on the use of combinatorial ligand libraries of 
hexapeptides bound to a chromatographic support. [201] The ligand libraries consist of 
lO^-lO'^ unique peptide ligands which greatly enhance the number and variety of 
proteins being captured. In the past, due to the relative abundance issue, high abundance 
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proteins had a higher chance to be captured and analyzed than low abundance proteins. 
With the new technology, the high abundance proteins stop being captured when the 
binding sites of the specify beads are saturated. 
In the future, combined use of Equalizer beads and our magnetic beads technology 
should allow the discovery of low abundance proteins as potential biomarkers. The 
serum can be first treated by Equalizer beads to enrich the low abundance proteins. The 
fraction is then subjected to magnetic beads protein profiling for biomarker discovery. It 
is believed that the relative concentration differences of the low abundance proteins 
between disease and control groups should remain approximately unchanged if these 
low abundance proteins were not saturated on the beads. [200] The main drawback of 
this technology is large volume of plasma/serum (e.g. ImL) is needed for the enrichment 
of low abundance proteins, and the current technology can only be performed manually. 
If the magnetic property is added to the Equalizer beads, our developed method can be 
adopted so that automation of enrichment together with purification can be done on the 
Kingfisher 96 platform. Besides applying 2-D PAGE for protein identification, gel-free 
shotgun proteomics approach can be used instead. The eluted fraction can be subjected 
to 2-D LC for protein identification using MudPIT approach. The fraction was first 
digested and then separated by SCX and reversed phase columns. This approach can 
greatly reduce sample loss and high coverage of protein can be obtained. 
Although our current magnetic beads-based profiling technology and the SELDI-
TOF technology cannot provide quantitative information of the low abundance proteins, 
the identification of disease-specific variants may help to improve the specificity of the 
proteomic fingerprints for disease diagnoses. Both SELDI and magnetic bead profiling 
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are capable of differentiating low molecular weight protein variants having different 
post-translation modification(s). Some variants could be disease-associated. For 
example, des-Ala-fibrinopeptide A (m/z 1,466), was found to be a potential liver cancer 
marker [202] and fibrinogen a-chain (m/z 2,664) was a potential biomarker for oral 
cancer. [84] These protein variants are too small to be analyzed using traditional 2-D 
PAGE technique. 
In our study, apo C-III variants were detected as a biomarker in detecting liver 
fibrosis which was undergone sialylation. Though three variants were correlated with 
the degrees of liver fibrosis, the hyposialylated apo C-III variant appeared as the best 
marker. It is well known that it is difficult to develop a glycoform-specific assay using 
the conventional immunoassay technology. If one wants to only quantify a specific apo 
C-III variant, one will need to develop glycosylation immunosorbent assay [203], MS 
immunoassay [204], or multiple reaction monitoring assay. [205] MRM can be done for 
further investigation on isoform characterization and relative quantitation of apo C-III 
isoforms. 
In clinical point of view, our result has suggested that our diagnostic model can be 
used as a screening test for liver fibrosis. Blood test is cheaper and more versatile 
compared with other non-invasive tests such as FibroScan. As FibroScan is proved as a 
stable and accurate method in predicting liver fibrosis, it may be a good alternative to 
reduce liver biopsy. However, specialist is required to perform the FibroScan test, 
leading to lower turn around time and higher running cost. Therefore, in order to shorten 
the waiting time and running cost, blood test can be introduced as the first line screening 
test. Patients can first do a routine blood test in the clinics for routine check. Those 
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patients with blood test result falling in the grey area will be followed up with FibroScan. 
Finally, the highly suspected cases will be confirmed by histological examination of 
liver biopsies. This approach can remarkably decrease the hospital expense. 
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Conclusion 
In conclusion, a novel magnetic beads-based proteomic profiling method was 
successfully developed, and proven to be a useful tool in biomarker discovery. With the 
developed methodology, a proteomic fingerprint composed of 2 protein markers was 
found in patients with CHB-associated liver fibrosis, and could be used as a diagnostic 
marker with good accuracy. The predictive model was treat-independent which would 
not be affected by anti-viral treatment. It could be considered as a screening test for 
detecting liver fibrosis. With our classification strategy, those patients in high risk and 
low risk group can be excluded from the examination of liver biopsy. Liver biopsy and 
hospital expense can be reduced under this strategy. Apo C-III was identified to be one 
of the protein markers. Subsequently, we showed that serum Apo C-III and Apo A-II 
concentration were decreased in the CHB patients with liver fibrosis. As both apo A-II 
and apo C-III were regulated by HNF-4a, it was believed that HNF-4a maybe a key 
factor for liver fibrosis. 
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